Source Name	Characteristics[organism]	Characteristics[organism part]	Characteristics[age]	Characteristics[developmental stage]	Characteristics[sex]	Characteristics[ancestry category]	Characteristics[disease]	Characteristics[cell type]	Characteristics[cell line]	Characteristics[treatment]	Characteristics[treatment]	Characteristics[enrichment method]	Characteristics[enrichment process]	assay name	comment[label]	comment[file uri]	comment[fractionation method]	comment[fraction identifier]	comment[instrument]	comment[modification parameters]	comment[modification parameters]	comment[modification parameters]	comment[modification parameters]	comment[cleavage agent details]	comment[cleavage agent details]	comment[fragment mass tolerance]	comment[precursor mass tolerance]	comment[data file]	Material Type	factor value[enrichment process]	factor value[treatment]	factor value[treatment]
Sample 1	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	BRAF inhibitor dabrafenib	TIO2	enrichment of phosphorylated Protein	run 1	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131114_CCS_EV_A375_RAFi_30min_S01.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	1	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131114_CCS_EV_A375_RAFi_30min_S01.raw	cell	enrichment of phosphorylated Protein	none	BRAF inhibitor dabrafenib
Sample 1	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	BRAF inhibitor dabrafenib	TIO2	enrichment of phosphorylated Protein	run 1	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131114_CCS_EV_A375_RAFi_30min_S01.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	1	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131114_CCS_EV_A375_RAFi_30min_S01.raw	cell	enrichment of phosphorylated Protein	control	BRAF inhibitor dabrafenib
Sample 1	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	enrichment of phosphorylated Protein	run 1	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131114_CCS_EV_A375_RAFi_30min_S01.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	1	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131114_CCS_EV_A375_RAFi_30min_S01.raw	cell	enrichment of phosphorylated Protein	none	control
Sample 1	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	BRAF inhibitor dabrafenib	TIO2	enrichment of phosphorylated Protein	run 2	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131114_CCS_EV_A375_RAFi_30min_S013_14.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	6	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131114_CCS_EV_A375_RAFi_30min_S013_14.raw	cell	enrichment of phosphorylated Protein	none	BRAF inhibitor dabrafenib
Sample 1	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	BRAF inhibitor dabrafenib	TIO2	enrichment of phosphorylated Protein	run 2	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131114_CCS_EV_A375_RAFi_30min_S013_14.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	6	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131114_CCS_EV_A375_RAFi_30min_S013_14.raw	cell	enrichment of phosphorylated Protein	control	BRAF inhibitor dabrafenib
Sample 1	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	enrichment of phosphorylated Protein	run 2	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131114_CCS_EV_A375_RAFi_30min_S013_14.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	6	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131114_CCS_EV_A375_RAFi_30min_S013_14.raw	cell	enrichment of phosphorylated Protein	none	control
Sample 1	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	BRAF inhibitor dabrafenib	TIO2	enrichment of phosphorylated Protein	run 3	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131114_CCS_EV_A375_RAFi_30min_S015.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	7	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131114_CCS_EV_A375_RAFi_30min_S015.raw	cell	enrichment of phosphorylated Protein	none	BRAF inhibitor dabrafenib
Sample 1	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	BRAF inhibitor dabrafenib	TIO2	enrichment of phosphorylated Protein	run 3	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131114_CCS_EV_A375_RAFi_30min_S015.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	7	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131114_CCS_EV_A375_RAFi_30min_S015.raw	cell	enrichment of phosphorylated Protein	control	BRAF inhibitor dabrafenib
Sample 1	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	enrichment of phosphorylated Protein	run 3	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131114_CCS_EV_A375_RAFi_30min_S015.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	7	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131114_CCS_EV_A375_RAFi_30min_S015.raw	cell	enrichment of phosphorylated Protein	none	control
Sample 1	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	BRAF inhibitor dabrafenib	TIO2	enrichment of phosphorylated Protein	run 4	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131114_CCS_EV_A375_RAFi_30min_S02_12.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	2	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131114_CCS_EV_A375_RAFi_30min_S02_12.raw	cell	enrichment of phosphorylated Protein	none	BRAF inhibitor dabrafenib
Sample 1	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	BRAF inhibitor dabrafenib	TIO2	enrichment of phosphorylated Protein	run 4	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131114_CCS_EV_A375_RAFi_30min_S02_12.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	2	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131114_CCS_EV_A375_RAFi_30min_S02_12.raw	cell	enrichment of phosphorylated Protein	control	BRAF inhibitor dabrafenib
Sample 1	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	enrichment of phosphorylated Protein	run 4	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131114_CCS_EV_A375_RAFi_30min_S02_12.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	2	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131114_CCS_EV_A375_RAFi_30min_S02_12.raw	cell	enrichment of phosphorylated Protein	none	control
Sample 1	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	BRAF inhibitor dabrafenib	TIO2	enrichment of phosphorylated Protein	run 5	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131114_CCS_EV_A375_RAFi_30min_S03_4_5_6.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	3	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131114_CCS_EV_A375_RAFi_30min_S03_4_5_6.raw	cell	enrichment of phosphorylated Protein	none	BRAF inhibitor dabrafenib
Sample 1	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	BRAF inhibitor dabrafenib	TIO2	enrichment of phosphorylated Protein	run 5	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131114_CCS_EV_A375_RAFi_30min_S03_4_5_6.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	3	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131114_CCS_EV_A375_RAFi_30min_S03_4_5_6.raw	cell	enrichment of phosphorylated Protein	control	BRAF inhibitor dabrafenib
Sample 1	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	enrichment of phosphorylated Protein	run 5	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131114_CCS_EV_A375_RAFi_30min_S03_4_5_6.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	3	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131114_CCS_EV_A375_RAFi_30min_S03_4_5_6.raw	cell	enrichment of phosphorylated Protein	none	control
Sample 1	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	BRAF inhibitor dabrafenib	TIO2	enrichment of phosphorylated Protein	run 6	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131114_CCS_EV_A375_RAFi_30min_S07_8.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	4	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131114_CCS_EV_A375_RAFi_30min_S07_8.raw	cell	enrichment of phosphorylated Protein	none	BRAF inhibitor dabrafenib
Sample 1	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	BRAF inhibitor dabrafenib	TIO2	enrichment of phosphorylated Protein	run 6	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131114_CCS_EV_A375_RAFi_30min_S07_8.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	4	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131114_CCS_EV_A375_RAFi_30min_S07_8.raw	cell	enrichment of phosphorylated Protein	control	BRAF inhibitor dabrafenib
Sample 1	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	enrichment of phosphorylated Protein	run 6	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131114_CCS_EV_A375_RAFi_30min_S07_8.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	4	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131114_CCS_EV_A375_RAFi_30min_S07_8.raw	cell	enrichment of phosphorylated Protein	none	control
Sample 1	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	BRAF inhibitor dabrafenib	TIO2	enrichment of phosphorylated Protein	run 7	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131114_CCS_EV_A375_RAFi_30min_S09_10_11.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	5	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131114_CCS_EV_A375_RAFi_30min_S09_10_11.raw	cell	enrichment of phosphorylated Protein	none	BRAF inhibitor dabrafenib
Sample 1	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	BRAF inhibitor dabrafenib	TIO2	enrichment of phosphorylated Protein	run 7	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131114_CCS_EV_A375_RAFi_30min_S09_10_11.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	5	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131114_CCS_EV_A375_RAFi_30min_S09_10_11.raw	cell	enrichment of phosphorylated Protein	control	BRAF inhibitor dabrafenib
Sample 1	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	enrichment of phosphorylated Protein	run 7	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131114_CCS_EV_A375_RAFi_30min_S09_10_11.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	5	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131114_CCS_EV_A375_RAFi_30min_S09_10_11.raw	cell	enrichment of phosphorylated Protein	none	control
Sample 2	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	ERK inhibitor SCH772984	TIO2	enrichment of phosphorylated Protein	run 8	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131116_CCs_EV_A375_ERKi_30min_S01.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	1	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131116_CCs_EV_A375_ERKi_30min_S01.raw	cell	enrichment of phosphorylated Protein	none	ERK inhibitor SCH772984
Sample 2	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	ERK inhibitor SCH772984	TIO2	enrichment of phosphorylated Protein	run 8	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131116_CCs_EV_A375_ERKi_30min_S01.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	1	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131116_CCs_EV_A375_ERKi_30min_S01.raw	cell	enrichment of phosphorylated Protein	control	ERK inhibitor SCH772984
Sample 2	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	enrichment of phosphorylated Protein	run 8	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131116_CCs_EV_A375_ERKi_30min_S01.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	1	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131116_CCs_EV_A375_ERKi_30min_S01.raw	cell	enrichment of phosphorylated Protein	none	control
Sample 2	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	ERK inhibitor SCH772984	TIO2	enrichment of phosphorylated Protein	run 9	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131116_CCs_EV_A375_ERKi_30min_S013_14.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	6	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131116_CCs_EV_A375_ERKi_30min_S013_14.raw	cell	enrichment of phosphorylated Protein	none	ERK inhibitor SCH772984
Sample 2	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	ERK inhibitor SCH772984	TIO2	enrichment of phosphorylated Protein	run 9	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131116_CCs_EV_A375_ERKi_30min_S013_14.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	6	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131116_CCs_EV_A375_ERKi_30min_S013_14.raw	cell	enrichment of phosphorylated Protein	control	ERK inhibitor SCH772984
Sample 2	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	enrichment of phosphorylated Protein	run 9	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131116_CCs_EV_A375_ERKi_30min_S013_14.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	6	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131116_CCs_EV_A375_ERKi_30min_S013_14.raw	cell	enrichment of phosphorylated Protein	none	control
Sample 2	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	ERK inhibitor SCH772984	TIO2	enrichment of phosphorylated Protein	run 10	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131116_CCs_EV_A375_ERKi_30min_S013_14_131122203229.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	6	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131116_CCs_EV_A375_ERKi_30min_S013_14_131122203229.raw	cell	enrichment of phosphorylated Protein	none	ERK inhibitor SCH772984
Sample 2	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	ERK inhibitor SCH772984	TIO2	enrichment of phosphorylated Protein	run 10	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131116_CCs_EV_A375_ERKi_30min_S013_14_131122203229.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	6	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131116_CCs_EV_A375_ERKi_30min_S013_14_131122203229.raw	cell	enrichment of phosphorylated Protein	control	ERK inhibitor SCH772984
Sample 2	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	enrichment of phosphorylated Protein	run 10	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131116_CCs_EV_A375_ERKi_30min_S013_14_131122203229.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	6	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131116_CCs_EV_A375_ERKi_30min_S013_14_131122203229.raw	cell	enrichment of phosphorylated Protein	none	control
Sample 2	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	ERK inhibitor SCH772984	TIO2	enrichment of phosphorylated Protein	run 11	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131116_CCs_EV_A375_ERKi_30min_S015.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	7	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131116_CCs_EV_A375_ERKi_30min_S015.raw	cell	enrichment of phosphorylated Protein	none	ERK inhibitor SCH772984
Sample 2	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	ERK inhibitor SCH772984	TIO2	enrichment of phosphorylated Protein	run 11	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131116_CCs_EV_A375_ERKi_30min_S015.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	7	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131116_CCs_EV_A375_ERKi_30min_S015.raw	cell	enrichment of phosphorylated Protein	control	ERK inhibitor SCH772984
Sample 2	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	enrichment of phosphorylated Protein	run 11	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131116_CCs_EV_A375_ERKi_30min_S015.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	7	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131116_CCs_EV_A375_ERKi_30min_S015.raw	cell	enrichment of phosphorylated Protein	none	control
Sample 2	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	ERK inhibitor SCH772984	TIO2	enrichment of phosphorylated Protein	run 12	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131116_CCs_EV_A375_ERKi_30min_S015_131123012154.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	7	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131116_CCs_EV_A375_ERKi_30min_S015_131123012154.raw	cell	enrichment of phosphorylated Protein	none	ERK inhibitor SCH772984
Sample 2	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	ERK inhibitor SCH772984	TIO2	enrichment of phosphorylated Protein	run 12	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131116_CCs_EV_A375_ERKi_30min_S015_131123012154.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	7	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131116_CCs_EV_A375_ERKi_30min_S015_131123012154.raw	cell	enrichment of phosphorylated Protein	control	ERK inhibitor SCH772984
Sample 2	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	enrichment of phosphorylated Protein	run 12	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131116_CCs_EV_A375_ERKi_30min_S015_131123012154.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	7	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131116_CCs_EV_A375_ERKi_30min_S015_131123012154.raw	cell	enrichment of phosphorylated Protein	none	control
Sample 2	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	ERK inhibitor SCH772984	TIO2	enrichment of phosphorylated Protein	run 13	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131116_CCs_EV_A375_ERKi_30min_S01_131121210011.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	1	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131116_CCs_EV_A375_ERKi_30min_S01_131121210011.raw	cell	enrichment of phosphorylated Protein	none	ERK inhibitor SCH772984
Sample 2	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	ERK inhibitor SCH772984	TIO2	enrichment of phosphorylated Protein	run 13	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131116_CCs_EV_A375_ERKi_30min_S01_131121210011.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	1	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131116_CCs_EV_A375_ERKi_30min_S01_131121210011.raw	cell	enrichment of phosphorylated Protein	control	ERK inhibitor SCH772984
Sample 2	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	enrichment of phosphorylated Protein	run 13	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131116_CCs_EV_A375_ERKi_30min_S01_131121210011.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	1	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131116_CCs_EV_A375_ERKi_30min_S01_131121210011.raw	cell	enrichment of phosphorylated Protein	none	control
Sample 2	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	ERK inhibitor SCH772984	TIO2	enrichment of phosphorylated Protein	run 14	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131116_CCs_EV_A375_ERKi_30min_S02_12.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	2	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131116_CCs_EV_A375_ERKi_30min_S02_12.raw	cell	enrichment of phosphorylated Protein	none	ERK inhibitor SCH772984
Sample 2	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	ERK inhibitor SCH772984	TIO2	enrichment of phosphorylated Protein	run 14	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131116_CCs_EV_A375_ERKi_30min_S02_12.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	2	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131116_CCs_EV_A375_ERKi_30min_S02_12.raw	cell	enrichment of phosphorylated Protein	control	ERK inhibitor SCH772984
Sample 2	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	enrichment of phosphorylated Protein	run 14	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131116_CCs_EV_A375_ERKi_30min_S02_12.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	2	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131116_CCs_EV_A375_ERKi_30min_S02_12.raw	cell	enrichment of phosphorylated Protein	none	control
Sample 2	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	ERK inhibitor SCH772984	TIO2	enrichment of phosphorylated Protein	run 15	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131116_CCs_EV_A375_ERKi_30min_S02_12_131122013411.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	2	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131116_CCs_EV_A375_ERKi_30min_S02_12_131122013411.raw	cell	enrichment of phosphorylated Protein	none	ERK inhibitor SCH772984
Sample 2	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	ERK inhibitor SCH772984	TIO2	enrichment of phosphorylated Protein	run 15	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131116_CCs_EV_A375_ERKi_30min_S02_12_131122013411.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	2	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131116_CCs_EV_A375_ERKi_30min_S02_12_131122013411.raw	cell	enrichment of phosphorylated Protein	control	ERK inhibitor SCH772984
Sample 2	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	enrichment of phosphorylated Protein	run 15	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131116_CCs_EV_A375_ERKi_30min_S02_12_131122013411.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	2	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131116_CCs_EV_A375_ERKi_30min_S02_12_131122013411.raw	cell	enrichment of phosphorylated Protein	none	control
Sample 2	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	ERK inhibitor SCH772984	TIO2	enrichment of phosphorylated Protein	run 16	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131116_CCs_EV_A375_ERKi_30min_S03_4_5_6.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	3	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131116_CCs_EV_A375_ERKi_30min_S03_4_5_6.raw	cell	enrichment of phosphorylated Protein	none	ERK inhibitor SCH772984
Sample 2	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	ERK inhibitor SCH772984	TIO2	enrichment of phosphorylated Protein	run 16	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131116_CCs_EV_A375_ERKi_30min_S03_4_5_6.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	3	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131116_CCs_EV_A375_ERKi_30min_S03_4_5_6.raw	cell	enrichment of phosphorylated Protein	control	ERK inhibitor SCH772984
Sample 2	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	enrichment of phosphorylated Protein	run 16	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131116_CCs_EV_A375_ERKi_30min_S03_4_5_6.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	3	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131116_CCs_EV_A375_ERKi_30min_S03_4_5_6.raw	cell	enrichment of phosphorylated Protein	none	control
Sample 2	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	ERK inhibitor SCH772984	TIO2	enrichment of phosphorylated Protein	run 17	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131116_CCs_EV_A375_ERKi_30min_S03_4_5_6_131122061521.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	3	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131116_CCs_EV_A375_ERKi_30min_S03_4_5_6_131122061521.raw	cell	enrichment of phosphorylated Protein	none	ERK inhibitor SCH772984
Sample 2	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	ERK inhibitor SCH772984	TIO2	enrichment of phosphorylated Protein	run 17	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131116_CCs_EV_A375_ERKi_30min_S03_4_5_6_131122061521.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	3	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131116_CCs_EV_A375_ERKi_30min_S03_4_5_6_131122061521.raw	cell	enrichment of phosphorylated Protein	control	ERK inhibitor SCH772984
Sample 2	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	enrichment of phosphorylated Protein	run 17	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131116_CCs_EV_A375_ERKi_30min_S03_4_5_6_131122061521.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	3	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131116_CCs_EV_A375_ERKi_30min_S03_4_5_6_131122061521.raw	cell	enrichment of phosphorylated Protein	none	control
Sample 2	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	ERK inhibitor SCH772984	TIO2	enrichment of phosphorylated Protein	run 18	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131116_CCs_EV_A375_ERKi_30min_S07_8.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	4	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131116_CCs_EV_A375_ERKi_30min_S07_8.raw	cell	enrichment of phosphorylated Protein	none	ERK inhibitor SCH772984
Sample 2	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	ERK inhibitor SCH772984	TIO2	enrichment of phosphorylated Protein	run 18	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131116_CCs_EV_A375_ERKi_30min_S07_8.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	4	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131116_CCs_EV_A375_ERKi_30min_S07_8.raw	cell	enrichment of phosphorylated Protein	control	ERK inhibitor SCH772984
Sample 2	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	enrichment of phosphorylated Protein	run 18	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131116_CCs_EV_A375_ERKi_30min_S07_8.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	4	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131116_CCs_EV_A375_ERKi_30min_S07_8.raw	cell	enrichment of phosphorylated Protein	none	control
Sample 2	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	ERK inhibitor SCH772984	TIO2	enrichment of phosphorylated Protein	run 19	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131116_CCs_EV_A375_ERKi_30min_S07_8_131122105649.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	4	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131116_CCs_EV_A375_ERKi_30min_S07_8_131122105649.raw	cell	enrichment of phosphorylated Protein	none	ERK inhibitor SCH772984
Sample 2	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	ERK inhibitor SCH772984	TIO2	enrichment of phosphorylated Protein	run 19	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131116_CCs_EV_A375_ERKi_30min_S07_8_131122105649.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	4	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131116_CCs_EV_A375_ERKi_30min_S07_8_131122105649.raw	cell	enrichment of phosphorylated Protein	control	ERK inhibitor SCH772984
Sample 2	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	enrichment of phosphorylated Protein	run 19	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131116_CCs_EV_A375_ERKi_30min_S07_8_131122105649.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	4	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131116_CCs_EV_A375_ERKi_30min_S07_8_131122105649.raw	cell	enrichment of phosphorylated Protein	none	control
Sample 2	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	ERK inhibitor SCH772984	TIO2	enrichment of phosphorylated Protein	run 20	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131116_CCs_EV_A375_ERKi_30min_S09_10_11.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	5	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131116_CCs_EV_A375_ERKi_30min_S09_10_11.raw	cell	enrichment of phosphorylated Protein	none	ERK inhibitor SCH772984
Sample 2	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	ERK inhibitor SCH772984	TIO2	enrichment of phosphorylated Protein	run 20	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131116_CCs_EV_A375_ERKi_30min_S09_10_11.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	5	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131116_CCs_EV_A375_ERKi_30min_S09_10_11.raw	cell	enrichment of phosphorylated Protein	control	ERK inhibitor SCH772984
Sample 2	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	enrichment of phosphorylated Protein	run 20	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131116_CCs_EV_A375_ERKi_30min_S09_10_11.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	5	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131116_CCs_EV_A375_ERKi_30min_S09_10_11.raw	cell	enrichment of phosphorylated Protein	none	control
Sample 2	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	ERK inhibitor SCH772984	TIO2	enrichment of phosphorylated Protein	run 21	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131116_CCs_EV_A375_ERKi_30min_S09_10_11_131122154332.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	5	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131116_CCs_EV_A375_ERKi_30min_S09_10_11_131122154332.raw	cell	enrichment of phosphorylated Protein	none	ERK inhibitor SCH772984
Sample 2	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	ERK inhibitor SCH772984	TIO2	enrichment of phosphorylated Protein	run 21	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131116_CCs_EV_A375_ERKi_30min_S09_10_11_131122154332.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	5	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131116_CCs_EV_A375_ERKi_30min_S09_10_11_131122154332.raw	cell	enrichment of phosphorylated Protein	control	ERK inhibitor SCH772984
Sample 2	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	enrichment of phosphorylated Protein	run 21	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131116_CCs_EV_A375_ERKi_30min_S09_10_11_131122154332.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	5	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131116_CCs_EV_A375_ERKi_30min_S09_10_11_131122154332.raw	cell	enrichment of phosphorylated Protein	none	control
Sample 3	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	MEK inhibitor trametinib	TIO2	enrichment of phosphorylated Protein	run 22	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131116_CCs_EV_A375_MEKi_30min_S01.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	1	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131116_CCs_EV_A375_MEKi_30min_S01.raw	cell	enrichment of phosphorylated Protein	none	MEK inhibitor trametinib
Sample 3	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	MEK inhibitor trametinib	TIO2	enrichment of phosphorylated Protein	run 22	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131116_CCs_EV_A375_MEKi_30min_S01.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	1	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131116_CCs_EV_A375_MEKi_30min_S01.raw	cell	enrichment of phosphorylated Protein	control	MEK inhibitor trametinib
Sample 3	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	enrichment of phosphorylated Protein	run 22	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131116_CCs_EV_A375_MEKi_30min_S01.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	1	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131116_CCs_EV_A375_MEKi_30min_S01.raw	cell	enrichment of phosphorylated Protein	none	control
Sample 3	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	MEK inhibitor trametinib	TIO2	enrichment of phosphorylated Protein	run 23	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131116_CCs_EV_A375_MEKi_30min_S013_14.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	6	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131116_CCs_EV_A375_MEKi_30min_S013_14.raw	cell	enrichment of phosphorylated Protein	none	MEK inhibitor trametinib
Sample 3	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	MEK inhibitor trametinib	TIO2	enrichment of phosphorylated Protein	run 23	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131116_CCs_EV_A375_MEKi_30min_S013_14.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	6	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131116_CCs_EV_A375_MEKi_30min_S013_14.raw	cell	enrichment of phosphorylated Protein	control	MEK inhibitor trametinib
Sample 3	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	enrichment of phosphorylated Protein	run 23	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131116_CCs_EV_A375_MEKi_30min_S013_14.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	6	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131116_CCs_EV_A375_MEKi_30min_S013_14.raw	cell	enrichment of phosphorylated Protein	none	control
Sample 3	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	MEK inhibitor trametinib	TIO2	enrichment of phosphorylated Protein	run 24	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131116_CCs_EV_A375_MEKi_30min_S015.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	7	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131116_CCs_EV_A375_MEKi_30min_S015.raw	cell	enrichment of phosphorylated Protein	none	MEK inhibitor trametinib
Sample 3	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	MEK inhibitor trametinib	TIO2	enrichment of phosphorylated Protein	run 24	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131116_CCs_EV_A375_MEKi_30min_S015.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	7	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131116_CCs_EV_A375_MEKi_30min_S015.raw	cell	enrichment of phosphorylated Protein	control	MEK inhibitor trametinib
Sample 3	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	enrichment of phosphorylated Protein	run 24	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131116_CCs_EV_A375_MEKi_30min_S015.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	7	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131116_CCs_EV_A375_MEKi_30min_S015.raw	cell	enrichment of phosphorylated Protein	none	control
Sample 3	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	MEK inhibitor trametinib	TIO2	enrichment of phosphorylated Protein	run 25	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131116_CCs_EV_A375_MEKi_30min_S02_12.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	2	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131116_CCs_EV_A375_MEKi_30min_S02_12.raw	cell	enrichment of phosphorylated Protein	none	MEK inhibitor trametinib
Sample 3	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	MEK inhibitor trametinib	TIO2	enrichment of phosphorylated Protein	run 25	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131116_CCs_EV_A375_MEKi_30min_S02_12.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	2	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131116_CCs_EV_A375_MEKi_30min_S02_12.raw	cell	enrichment of phosphorylated Protein	control	MEK inhibitor trametinib
Sample 3	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	enrichment of phosphorylated Protein	run 25	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131116_CCs_EV_A375_MEKi_30min_S02_12.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	2	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131116_CCs_EV_A375_MEKi_30min_S02_12.raw	cell	enrichment of phosphorylated Protein	none	control
Sample 3	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	MEK inhibitor trametinib	TIO2	enrichment of phosphorylated Protein	run 26	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131116_CCs_EV_A375_MEKi_30min_S03_4_5_6.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	3	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131116_CCs_EV_A375_MEKi_30min_S03_4_5_6.raw	cell	enrichment of phosphorylated Protein	none	MEK inhibitor trametinib
Sample 3	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	MEK inhibitor trametinib	TIO2	enrichment of phosphorylated Protein	run 26	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131116_CCs_EV_A375_MEKi_30min_S03_4_5_6.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	3	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131116_CCs_EV_A375_MEKi_30min_S03_4_5_6.raw	cell	enrichment of phosphorylated Protein	control	MEK inhibitor trametinib
Sample 3	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	enrichment of phosphorylated Protein	run 26	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131116_CCs_EV_A375_MEKi_30min_S03_4_5_6.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	3	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131116_CCs_EV_A375_MEKi_30min_S03_4_5_6.raw	cell	enrichment of phosphorylated Protein	none	control
Sample 3	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	MEK inhibitor trametinib	TIO2	enrichment of phosphorylated Protein	run 27	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131116_CCs_EV_A375_MEKi_30min_S07_8.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	4	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131116_CCs_EV_A375_MEKi_30min_S07_8.raw	cell	enrichment of phosphorylated Protein	none	MEK inhibitor trametinib
Sample 3	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	MEK inhibitor trametinib	TIO2	enrichment of phosphorylated Protein	run 27	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131116_CCs_EV_A375_MEKi_30min_S07_8.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	4	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131116_CCs_EV_A375_MEKi_30min_S07_8.raw	cell	enrichment of phosphorylated Protein	control	MEK inhibitor trametinib
Sample 3	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	enrichment of phosphorylated Protein	run 27	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131116_CCs_EV_A375_MEKi_30min_S07_8.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	4	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131116_CCs_EV_A375_MEKi_30min_S07_8.raw	cell	enrichment of phosphorylated Protein	none	control
Sample 3	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	MEK inhibitor trametinib	TIO2	enrichment of phosphorylated Protein	run 28	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131116_CCs_EV_A375_MEKi_30min_S09_10_11.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	5	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131116_CCs_EV_A375_MEKi_30min_S09_10_11.raw	cell	enrichment of phosphorylated Protein	none	MEK inhibitor trametinib
Sample 3	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	MEK inhibitor trametinib	TIO2	enrichment of phosphorylated Protein	run 28	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131116_CCs_EV_A375_MEKi_30min_S09_10_11.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	5	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131116_CCs_EV_A375_MEKi_30min_S09_10_11.raw	cell	enrichment of phosphorylated Protein	control	MEK inhibitor trametinib
Sample 3	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	enrichment of phosphorylated Protein	run 28	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20131116_CCs_EV_A375_MEKi_30min_S09_10_11.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	5	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20131116_CCs_EV_A375_MEKi_30min_S09_10_11.raw	cell	enrichment of phosphorylated Protein	none	control
Sample 4	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	MEK inhibitor trametinib	TIO2	enrichment of phosphorylated Protein	run 29	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_CCS_EV_A375_MEKi_30min_v4_S01.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	1	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_CCS_EV_A375_MEKi_30min_v4_S01.raw	cell	enrichment of phosphorylated Protein	none	MEK inhibitor trametinib
Sample 4	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	MEK inhibitor trametinib	TIO2	enrichment of phosphorylated Protein	run 29	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_CCS_EV_A375_MEKi_30min_v4_S01.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	1	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_CCS_EV_A375_MEKi_30min_v4_S01.raw	cell	enrichment of phosphorylated Protein	control	MEK inhibitor trametinib
Sample 4	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	enrichment of phosphorylated Protein	run 29	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_CCS_EV_A375_MEKi_30min_v4_S01.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	1	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_CCS_EV_A375_MEKi_30min_v4_S01.raw	cell	enrichment of phosphorylated Protein	none	control
Sample 4	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	MEK inhibitor trametinib	TIO2	enrichment of phosphorylated Protein	run 30	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_CCS_EV_A375_MEKi_30min_v4_S013_14.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	6	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_CCS_EV_A375_MEKi_30min_v4_S013_14.raw	cell	enrichment of phosphorylated Protein	none	MEK inhibitor trametinib
Sample 4	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	MEK inhibitor trametinib	TIO2	enrichment of phosphorylated Protein	run 30	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_CCS_EV_A375_MEKi_30min_v4_S013_14.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	6	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_CCS_EV_A375_MEKi_30min_v4_S013_14.raw	cell	enrichment of phosphorylated Protein	control	MEK inhibitor trametinib
Sample 4	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	enrichment of phosphorylated Protein	run 30	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_CCS_EV_A375_MEKi_30min_v4_S013_14.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	6	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_CCS_EV_A375_MEKi_30min_v4_S013_14.raw	cell	enrichment of phosphorylated Protein	none	control
Sample 4	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	MEK inhibitor trametinib	TIO2	enrichment of phosphorylated Protein	run 31	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_CCS_EV_A375_MEKi_30min_v4_S015.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	7	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_CCS_EV_A375_MEKi_30min_v4_S015.raw	cell	enrichment of phosphorylated Protein	none	MEK inhibitor trametinib
Sample 4	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	MEK inhibitor trametinib	TIO2	enrichment of phosphorylated Protein	run 31	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_CCS_EV_A375_MEKi_30min_v4_S015.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	7	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_CCS_EV_A375_MEKi_30min_v4_S015.raw	cell	enrichment of phosphorylated Protein	control	MEK inhibitor trametinib
Sample 4	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	enrichment of phosphorylated Protein	run 31	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_CCS_EV_A375_MEKi_30min_v4_S015.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	7	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_CCS_EV_A375_MEKi_30min_v4_S015.raw	cell	enrichment of phosphorylated Protein	none	control
Sample 4	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	MEK inhibitor trametinib	TIO2	enrichment of phosphorylated Protein	run 32	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_CCS_EV_A375_MEKi_30min_v4_S02_12.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	2	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_CCS_EV_A375_MEKi_30min_v4_S02_12.raw	cell	enrichment of phosphorylated Protein	none	MEK inhibitor trametinib
Sample 4	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	MEK inhibitor trametinib	TIO2	enrichment of phosphorylated Protein	run 32	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_CCS_EV_A375_MEKi_30min_v4_S02_12.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	2	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_CCS_EV_A375_MEKi_30min_v4_S02_12.raw	cell	enrichment of phosphorylated Protein	control	MEK inhibitor trametinib
Sample 4	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	enrichment of phosphorylated Protein	run 32	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_CCS_EV_A375_MEKi_30min_v4_S02_12.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	2	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_CCS_EV_A375_MEKi_30min_v4_S02_12.raw	cell	enrichment of phosphorylated Protein	none	control
Sample 4	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	MEK inhibitor trametinib	TIO2	enrichment of phosphorylated Protein	run 33	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_CCS_EV_A375_MEKi_30min_v4_S03_4_5_6.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	3	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_CCS_EV_A375_MEKi_30min_v4_S03_4_5_6.raw	cell	enrichment of phosphorylated Protein	none	MEK inhibitor trametinib
Sample 4	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	MEK inhibitor trametinib	TIO2	enrichment of phosphorylated Protein	run 33	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_CCS_EV_A375_MEKi_30min_v4_S03_4_5_6.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	3	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_CCS_EV_A375_MEKi_30min_v4_S03_4_5_6.raw	cell	enrichment of phosphorylated Protein	control	MEK inhibitor trametinib
Sample 4	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	enrichment of phosphorylated Protein	run 33	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_CCS_EV_A375_MEKi_30min_v4_S03_4_5_6.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	3	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_CCS_EV_A375_MEKi_30min_v4_S03_4_5_6.raw	cell	enrichment of phosphorylated Protein	none	control
Sample 4	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	MEK inhibitor trametinib	TIO2	enrichment of phosphorylated Protein	run 34	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_CCS_EV_A375_MEKi_30min_v4_S07_8.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	4	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_CCS_EV_A375_MEKi_30min_v4_S07_8.raw	cell	enrichment of phosphorylated Protein	none	MEK inhibitor trametinib
Sample 4	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	MEK inhibitor trametinib	TIO2	enrichment of phosphorylated Protein	run 34	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_CCS_EV_A375_MEKi_30min_v4_S07_8.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	4	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_CCS_EV_A375_MEKi_30min_v4_S07_8.raw	cell	enrichment of phosphorylated Protein	control	MEK inhibitor trametinib
Sample 4	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	enrichment of phosphorylated Protein	run 34	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_CCS_EV_A375_MEKi_30min_v4_S07_8.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	4	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_CCS_EV_A375_MEKi_30min_v4_S07_8.raw	cell	enrichment of phosphorylated Protein	none	control
Sample 4	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	MEK inhibitor trametinib	TIO2	enrichment of phosphorylated Protein	run 35	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_CCS_EV_A375_MEKi_30min_v4_S09_10_11.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	5	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_CCS_EV_A375_MEKi_30min_v4_S09_10_11.raw	cell	enrichment of phosphorylated Protein	none	MEK inhibitor trametinib
Sample 4	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	MEK inhibitor trametinib	TIO2	enrichment of phosphorylated Protein	run 35	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_CCS_EV_A375_MEKi_30min_v4_S09_10_11.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	5	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_CCS_EV_A375_MEKi_30min_v4_S09_10_11.raw	cell	enrichment of phosphorylated Protein	control	MEK inhibitor trametinib
Sample 4	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	enrichment of phosphorylated Protein	run 35	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_CCS_EV_A375_MEKi_30min_v4_S09_10_11.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	5	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_CCS_EV_A375_MEKi_30min_v4_S09_10_11.raw	cell	enrichment of phosphorylated Protein	none	control
Sample 5	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	BRAF inhibitor dabrafenib	TIO2	enrichment of phosphorylated Protein	run 36	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140320_CCS_EV_A375_RAFi_30min_v4_S01.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	1	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140320_CCS_EV_A375_RAFi_30min_v4_S01.raw	cell	enrichment of phosphorylated Protein	none	BRAF inhibitor dabrafenib
Sample 5	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	BRAF inhibitor dabrafenib	TIO2	enrichment of phosphorylated Protein	run 36	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140320_CCS_EV_A375_RAFi_30min_v4_S01.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	1	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140320_CCS_EV_A375_RAFi_30min_v4_S01.raw	cell	enrichment of phosphorylated Protein	control	BRAF inhibitor dabrafenib
Sample 5	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	enrichment of phosphorylated Protein	run 36	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140320_CCS_EV_A375_RAFi_30min_v4_S01.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	1	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140320_CCS_EV_A375_RAFi_30min_v4_S01.raw	cell	enrichment of phosphorylated Protein	none	control
Sample 5	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	BRAF inhibitor dabrafenib	TIO2	enrichment of phosphorylated Protein	run 37	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140320_CCS_EV_A375_RAFi_30min_v4_S013_14.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	6	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140320_CCS_EV_A375_RAFi_30min_v4_S013_14.raw	cell	enrichment of phosphorylated Protein	none	BRAF inhibitor dabrafenib
Sample 5	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	BRAF inhibitor dabrafenib	TIO2	enrichment of phosphorylated Protein	run 37	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140320_CCS_EV_A375_RAFi_30min_v4_S013_14.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	6	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140320_CCS_EV_A375_RAFi_30min_v4_S013_14.raw	cell	enrichment of phosphorylated Protein	control	BRAF inhibitor dabrafenib
Sample 5	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	enrichment of phosphorylated Protein	run 37	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140320_CCS_EV_A375_RAFi_30min_v4_S013_14.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	6	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140320_CCS_EV_A375_RAFi_30min_v4_S013_14.raw	cell	enrichment of phosphorylated Protein	none	control
Sample 5	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	BRAF inhibitor dabrafenib	TIO2	enrichment of phosphorylated Protein	run 38	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140320_CCS_EV_A375_RAFi_30min_v4_S015.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	7	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140320_CCS_EV_A375_RAFi_30min_v4_S015.raw	cell	enrichment of phosphorylated Protein	none	BRAF inhibitor dabrafenib
Sample 5	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	BRAF inhibitor dabrafenib	TIO2	enrichment of phosphorylated Protein	run 38	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140320_CCS_EV_A375_RAFi_30min_v4_S015.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	7	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140320_CCS_EV_A375_RAFi_30min_v4_S015.raw	cell	enrichment of phosphorylated Protein	control	BRAF inhibitor dabrafenib
Sample 5	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	enrichment of phosphorylated Protein	run 38	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140320_CCS_EV_A375_RAFi_30min_v4_S015.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	7	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140320_CCS_EV_A375_RAFi_30min_v4_S015.raw	cell	enrichment of phosphorylated Protein	none	control
Sample 5	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	BRAF inhibitor dabrafenib	TIO2	enrichment of phosphorylated Protein	run 39	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140320_CCS_EV_A375_RAFi_30min_v4_S02_12.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	2	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140320_CCS_EV_A375_RAFi_30min_v4_S02_12.raw	cell	enrichment of phosphorylated Protein	none	BRAF inhibitor dabrafenib
Sample 5	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	BRAF inhibitor dabrafenib	TIO2	enrichment of phosphorylated Protein	run 39	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140320_CCS_EV_A375_RAFi_30min_v4_S02_12.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	2	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140320_CCS_EV_A375_RAFi_30min_v4_S02_12.raw	cell	enrichment of phosphorylated Protein	control	BRAF inhibitor dabrafenib
Sample 5	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	enrichment of phosphorylated Protein	run 39	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140320_CCS_EV_A375_RAFi_30min_v4_S02_12.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	2	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140320_CCS_EV_A375_RAFi_30min_v4_S02_12.raw	cell	enrichment of phosphorylated Protein	none	control
Sample 5	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	BRAF inhibitor dabrafenib	TIO2	enrichment of phosphorylated Protein	run 40	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140320_CCS_EV_A375_RAFi_30min_v4_S03_4_5_6.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	3	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140320_CCS_EV_A375_RAFi_30min_v4_S03_4_5_6.raw	cell	enrichment of phosphorylated Protein	none	BRAF inhibitor dabrafenib
Sample 5	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	BRAF inhibitor dabrafenib	TIO2	enrichment of phosphorylated Protein	run 40	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140320_CCS_EV_A375_RAFi_30min_v4_S03_4_5_6.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	3	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140320_CCS_EV_A375_RAFi_30min_v4_S03_4_5_6.raw	cell	enrichment of phosphorylated Protein	control	BRAF inhibitor dabrafenib
Sample 5	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	enrichment of phosphorylated Protein	run 40	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140320_CCS_EV_A375_RAFi_30min_v4_S03_4_5_6.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	3	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140320_CCS_EV_A375_RAFi_30min_v4_S03_4_5_6.raw	cell	enrichment of phosphorylated Protein	none	control
Sample 5	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	BRAF inhibitor dabrafenib	TIO2	enrichment of phosphorylated Protein	run 41	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140320_CCS_EV_A375_RAFi_30min_v4_S07_8.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	4	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140320_CCS_EV_A375_RAFi_30min_v4_S07_8.raw	cell	enrichment of phosphorylated Protein	none	BRAF inhibitor dabrafenib
Sample 5	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	BRAF inhibitor dabrafenib	TIO2	enrichment of phosphorylated Protein	run 41	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140320_CCS_EV_A375_RAFi_30min_v4_S07_8.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	4	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140320_CCS_EV_A375_RAFi_30min_v4_S07_8.raw	cell	enrichment of phosphorylated Protein	control	BRAF inhibitor dabrafenib
Sample 5	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	enrichment of phosphorylated Protein	run 41	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140320_CCS_EV_A375_RAFi_30min_v4_S07_8.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	4	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140320_CCS_EV_A375_RAFi_30min_v4_S07_8.raw	cell	enrichment of phosphorylated Protein	none	control
Sample 5	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	BRAF inhibitor dabrafenib	TIO2	enrichment of phosphorylated Protein	run 42	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140320_CCS_EV_A375_RAFi_30min_v4_S09_10_11.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	5	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140320_CCS_EV_A375_RAFi_30min_v4_S09_10_11.raw	cell	enrichment of phosphorylated Protein	none	BRAF inhibitor dabrafenib
Sample 5	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	BRAF inhibitor dabrafenib	TIO2	enrichment of phosphorylated Protein	run 42	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140320_CCS_EV_A375_RAFi_30min_v4_S09_10_11.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	5	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140320_CCS_EV_A375_RAFi_30min_v4_S09_10_11.raw	cell	enrichment of phosphorylated Protein	control	BRAF inhibitor dabrafenib
Sample 5	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	enrichment of phosphorylated Protein	run 42	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140320_CCS_EV_A375_RAFi_30min_v4_S09_10_11.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	5	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140320_CCS_EV_A375_RAFi_30min_v4_S09_10_11.raw	cell	enrichment of phosphorylated Protein	none	control
Sample 6	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	BRAF inhibitor dabrafenib	TIO2	enrichment of phosphorylated Protein	run 43	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140207_KMJ_CCS_RAFi30min_V3_S01.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	1	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140207_KMJ_CCS_RAFi30min_V3_S01.raw	cell	enrichment of phosphorylated Protein	none	BRAF inhibitor dabrafenib
Sample 6	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	BRAF inhibitor dabrafenib	TIO2	enrichment of phosphorylated Protein	run 43	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140207_KMJ_CCS_RAFi30min_V3_S01.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	1	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140207_KMJ_CCS_RAFi30min_V3_S01.raw	cell	enrichment of phosphorylated Protein	control	BRAF inhibitor dabrafenib
Sample 6	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	enrichment of phosphorylated Protein	run 43	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140207_KMJ_CCS_RAFi30min_V3_S01.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	1	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140207_KMJ_CCS_RAFi30min_V3_S01.raw	cell	enrichment of phosphorylated Protein	none	control
Sample 6	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	BRAF inhibitor dabrafenib	TIO2	enrichment of phosphorylated Protein	run 44	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140207_KMJ_CCS_RAFi30min_V3_S013_14.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	6	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140207_KMJ_CCS_RAFi30min_V3_S013_14.raw	cell	enrichment of phosphorylated Protein	none	BRAF inhibitor dabrafenib
Sample 6	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	BRAF inhibitor dabrafenib	TIO2	enrichment of phosphorylated Protein	run 44	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140207_KMJ_CCS_RAFi30min_V3_S013_14.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	6	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140207_KMJ_CCS_RAFi30min_V3_S013_14.raw	cell	enrichment of phosphorylated Protein	control	BRAF inhibitor dabrafenib
Sample 6	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	enrichment of phosphorylated Protein	run 44	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140207_KMJ_CCS_RAFi30min_V3_S013_14.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	6	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140207_KMJ_CCS_RAFi30min_V3_S013_14.raw	cell	enrichment of phosphorylated Protein	none	control
Sample 6	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	BRAF inhibitor dabrafenib	TIO2	enrichment of phosphorylated Protein	run 45	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140207_KMJ_CCS_RAFi30min_V3_S015.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	7	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140207_KMJ_CCS_RAFi30min_V3_S015.raw	cell	enrichment of phosphorylated Protein	none	BRAF inhibitor dabrafenib
Sample 6	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	BRAF inhibitor dabrafenib	TIO2	enrichment of phosphorylated Protein	run 45	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140207_KMJ_CCS_RAFi30min_V3_S015.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	7	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140207_KMJ_CCS_RAFi30min_V3_S015.raw	cell	enrichment of phosphorylated Protein	control	BRAF inhibitor dabrafenib
Sample 6	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	enrichment of phosphorylated Protein	run 45	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140207_KMJ_CCS_RAFi30min_V3_S015.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	7	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140207_KMJ_CCS_RAFi30min_V3_S015.raw	cell	enrichment of phosphorylated Protein	none	control
Sample 6	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	BRAF inhibitor dabrafenib	TIO2	enrichment of phosphorylated Protein	run 46	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140207_KMJ_CCS_RAFi30min_V3_S02_12.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	2	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140207_KMJ_CCS_RAFi30min_V3_S02_12.raw	cell	enrichment of phosphorylated Protein	none	BRAF inhibitor dabrafenib
Sample 6	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	BRAF inhibitor dabrafenib	TIO2	enrichment of phosphorylated Protein	run 46	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140207_KMJ_CCS_RAFi30min_V3_S02_12.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	2	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140207_KMJ_CCS_RAFi30min_V3_S02_12.raw	cell	enrichment of phosphorylated Protein	control	BRAF inhibitor dabrafenib
Sample 6	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	enrichment of phosphorylated Protein	run 46	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140207_KMJ_CCS_RAFi30min_V3_S02_12.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	2	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140207_KMJ_CCS_RAFi30min_V3_S02_12.raw	cell	enrichment of phosphorylated Protein	none	control
Sample 6	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	BRAF inhibitor dabrafenib	TIO2	enrichment of phosphorylated Protein	run 47	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140207_KMJ_CCS_RAFi30min_V3_S03_4_5_6.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	3	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140207_KMJ_CCS_RAFi30min_V3_S03_4_5_6.raw	cell	enrichment of phosphorylated Protein	none	BRAF inhibitor dabrafenib
Sample 6	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	BRAF inhibitor dabrafenib	TIO2	enrichment of phosphorylated Protein	run 47	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140207_KMJ_CCS_RAFi30min_V3_S03_4_5_6.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	3	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140207_KMJ_CCS_RAFi30min_V3_S03_4_5_6.raw	cell	enrichment of phosphorylated Protein	control	BRAF inhibitor dabrafenib
Sample 6	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	enrichment of phosphorylated Protein	run 47	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140207_KMJ_CCS_RAFi30min_V3_S03_4_5_6.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	3	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140207_KMJ_CCS_RAFi30min_V3_S03_4_5_6.raw	cell	enrichment of phosphorylated Protein	none	control
Sample 6	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	BRAF inhibitor dabrafenib	TIO2	enrichment of phosphorylated Protein	run 48	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140207_KMJ_CCS_RAFi30min_V3_S07_8.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	4	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140207_KMJ_CCS_RAFi30min_V3_S07_8.raw	cell	enrichment of phosphorylated Protein	none	BRAF inhibitor dabrafenib
Sample 6	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	BRAF inhibitor dabrafenib	TIO2	enrichment of phosphorylated Protein	run 48	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140207_KMJ_CCS_RAFi30min_V3_S07_8.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	4	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140207_KMJ_CCS_RAFi30min_V3_S07_8.raw	cell	enrichment of phosphorylated Protein	control	BRAF inhibitor dabrafenib
Sample 6	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	enrichment of phosphorylated Protein	run 48	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140207_KMJ_CCS_RAFi30min_V3_S07_8.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	4	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140207_KMJ_CCS_RAFi30min_V3_S07_8.raw	cell	enrichment of phosphorylated Protein	none	control
Sample 6	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	BRAF inhibitor dabrafenib	TIO2	enrichment of phosphorylated Protein	run 49	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140207_KMJ_CCS_RAFi30min_V3_S09_10_11.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	5	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140207_KMJ_CCS_RAFi30min_V3_S09_10_11.raw	cell	enrichment of phosphorylated Protein	none	BRAF inhibitor dabrafenib
Sample 6	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	BRAF inhibitor dabrafenib	TIO2	enrichment of phosphorylated Protein	run 49	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140207_KMJ_CCS_RAFi30min_V3_S09_10_11.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	5	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140207_KMJ_CCS_RAFi30min_V3_S09_10_11.raw	cell	enrichment of phosphorylated Protein	control	BRAF inhibitor dabrafenib
Sample 6	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	enrichment of phosphorylated Protein	run 49	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140207_KMJ_CCS_RAFi30min_V3_S09_10_11.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	5	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140207_KMJ_CCS_RAFi30min_V3_S09_10_11.raw	cell	enrichment of phosphorylated Protein	none	control
Sample 7	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	MEK inhibitor trametinib	TIO2	enrichment of phosphorylated Protein	run 50	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140210_KMJ_CCS_MEKi30min_V3_S01.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	1	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140210_KMJ_CCS_MEKi30min_V3_S01.raw	cell	enrichment of phosphorylated Protein	none	MEK inhibitor trametinib
Sample 7	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	MEK inhibitor trametinib	TIO2	enrichment of phosphorylated Protein	run 50	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140210_KMJ_CCS_MEKi30min_V3_S01.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	1	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140210_KMJ_CCS_MEKi30min_V3_S01.raw	cell	enrichment of phosphorylated Protein	control	MEK inhibitor trametinib
Sample 7	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	enrichment of phosphorylated Protein	run 50	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140210_KMJ_CCS_MEKi30min_V3_S01.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	1	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140210_KMJ_CCS_MEKi30min_V3_S01.raw	cell	enrichment of phosphorylated Protein	none	control
Sample 7	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	MEK inhibitor trametinib	TIO2	enrichment of phosphorylated Protein	run 51	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140210_KMJ_CCS_MEKi30min_V3_S013_14.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	6	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140210_KMJ_CCS_MEKi30min_V3_S013_14.raw	cell	enrichment of phosphorylated Protein	none	MEK inhibitor trametinib
Sample 7	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	MEK inhibitor trametinib	TIO2	enrichment of phosphorylated Protein	run 51	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140210_KMJ_CCS_MEKi30min_V3_S013_14.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	6	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140210_KMJ_CCS_MEKi30min_V3_S013_14.raw	cell	enrichment of phosphorylated Protein	control	MEK inhibitor trametinib
Sample 7	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	enrichment of phosphorylated Protein	run 51	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140210_KMJ_CCS_MEKi30min_V3_S013_14.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	6	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140210_KMJ_CCS_MEKi30min_V3_S013_14.raw	cell	enrichment of phosphorylated Protein	none	control
Sample 7	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	MEK inhibitor trametinib	TIO2	enrichment of phosphorylated Protein	run 52	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140210_KMJ_CCS_MEKi30min_V3_S015.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	7	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140210_KMJ_CCS_MEKi30min_V3_S015.raw	cell	enrichment of phosphorylated Protein	none	MEK inhibitor trametinib
Sample 7	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	MEK inhibitor trametinib	TIO2	enrichment of phosphorylated Protein	run 52	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140210_KMJ_CCS_MEKi30min_V3_S015.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	7	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140210_KMJ_CCS_MEKi30min_V3_S015.raw	cell	enrichment of phosphorylated Protein	control	MEK inhibitor trametinib
Sample 7	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	enrichment of phosphorylated Protein	run 52	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140210_KMJ_CCS_MEKi30min_V3_S015.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	7	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140210_KMJ_CCS_MEKi30min_V3_S015.raw	cell	enrichment of phosphorylated Protein	none	control
Sample 7	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	MEK inhibitor trametinib	TIO2	enrichment of phosphorylated Protein	run 53	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140210_KMJ_CCS_MEKi30min_V3_S02_12.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	2	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140210_KMJ_CCS_MEKi30min_V3_S02_12.raw	cell	enrichment of phosphorylated Protein	none	MEK inhibitor trametinib
Sample 7	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	MEK inhibitor trametinib	TIO2	enrichment of phosphorylated Protein	run 53	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140210_KMJ_CCS_MEKi30min_V3_S02_12.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	2	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140210_KMJ_CCS_MEKi30min_V3_S02_12.raw	cell	enrichment of phosphorylated Protein	control	MEK inhibitor trametinib
Sample 7	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	enrichment of phosphorylated Protein	run 53	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140210_KMJ_CCS_MEKi30min_V3_S02_12.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	2	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140210_KMJ_CCS_MEKi30min_V3_S02_12.raw	cell	enrichment of phosphorylated Protein	none	control
Sample 7	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	MEK inhibitor trametinib	TIO2	enrichment of phosphorylated Protein	run 54	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140210_KMJ_CCS_MEKi30min_V3_S03_4_5_6.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	3	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140210_KMJ_CCS_MEKi30min_V3_S03_4_5_6.raw	cell	enrichment of phosphorylated Protein	none	MEK inhibitor trametinib
Sample 7	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	MEK inhibitor trametinib	TIO2	enrichment of phosphorylated Protein	run 54	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140210_KMJ_CCS_MEKi30min_V3_S03_4_5_6.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	3	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140210_KMJ_CCS_MEKi30min_V3_S03_4_5_6.raw	cell	enrichment of phosphorylated Protein	control	MEK inhibitor trametinib
Sample 7	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	enrichment of phosphorylated Protein	run 54	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140210_KMJ_CCS_MEKi30min_V3_S03_4_5_6.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	3	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140210_KMJ_CCS_MEKi30min_V3_S03_4_5_6.raw	cell	enrichment of phosphorylated Protein	none	control
Sample 7	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	MEK inhibitor trametinib	TIO2	enrichment of phosphorylated Protein	run 55	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140210_KMJ_CCS_MEKi30min_V3_S07_8.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	4	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140210_KMJ_CCS_MEKi30min_V3_S07_8.raw	cell	enrichment of phosphorylated Protein	none	MEK inhibitor trametinib
Sample 7	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	MEK inhibitor trametinib	TIO2	enrichment of phosphorylated Protein	run 55	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140210_KMJ_CCS_MEKi30min_V3_S07_8.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	4	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140210_KMJ_CCS_MEKi30min_V3_S07_8.raw	cell	enrichment of phosphorylated Protein	control	MEK inhibitor trametinib
Sample 7	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	enrichment of phosphorylated Protein	run 55	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140210_KMJ_CCS_MEKi30min_V3_S07_8.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	4	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140210_KMJ_CCS_MEKi30min_V3_S07_8.raw	cell	enrichment of phosphorylated Protein	none	control
Sample 7	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	MEK inhibitor trametinib	TIO2	enrichment of phosphorylated Protein	run 56	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140210_KMJ_CCS_MEKi30min_V3_S09_10_11.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	5	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140210_KMJ_CCS_MEKi30min_V3_S09_10_11.raw	cell	enrichment of phosphorylated Protein	none	MEK inhibitor trametinib
Sample 7	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	MEK inhibitor trametinib	TIO2	enrichment of phosphorylated Protein	run 56	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140210_KMJ_CCS_MEKi30min_V3_S09_10_11.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	5	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140210_KMJ_CCS_MEKi30min_V3_S09_10_11.raw	cell	enrichment of phosphorylated Protein	control	MEK inhibitor trametinib
Sample 7	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	enrichment of phosphorylated Protein	run 56	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140210_KMJ_CCS_MEKi30min_V3_S09_10_11.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	5	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140210_KMJ_CCS_MEKi30min_V3_S09_10_11.raw	cell	enrichment of phosphorylated Protein	none	control
Sample 8	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	ERK inhibitor SCH772984	TIO2	enrichment of phosphorylated Protein	run 57	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_KMJ_CCS_ERKi30min_V3_S01.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	1	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_KMJ_CCS_ERKi30min_V3_S01.raw	cell	enrichment of phosphorylated Protein	none	ERK inhibitor SCH772984
Sample 8	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	ERK inhibitor SCH772984	TIO2	enrichment of phosphorylated Protein	run 57	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_KMJ_CCS_ERKi30min_V3_S01.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	1	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_KMJ_CCS_ERKi30min_V3_S01.raw	cell	enrichment of phosphorylated Protein	control	ERK inhibitor SCH772984
Sample 8	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	enrichment of phosphorylated Protein	run 57	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_KMJ_CCS_ERKi30min_V3_S01.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	1	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_KMJ_CCS_ERKi30min_V3_S01.raw	cell	enrichment of phosphorylated Protein	none	control
Sample 8	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	ERK inhibitor SCH772984	TIO2	enrichment of phosphorylated Protein	run 58	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_KMJ_CCS_ERKi30min_V3_S013_14.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	6	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_KMJ_CCS_ERKi30min_V3_S013_14.raw	cell	enrichment of phosphorylated Protein	none	ERK inhibitor SCH772984
Sample 8	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	ERK inhibitor SCH772984	TIO2	enrichment of phosphorylated Protein	run 58	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_KMJ_CCS_ERKi30min_V3_S013_14.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	6	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_KMJ_CCS_ERKi30min_V3_S013_14.raw	cell	enrichment of phosphorylated Protein	control	ERK inhibitor SCH772984
Sample 8	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	enrichment of phosphorylated Protein	run 58	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_KMJ_CCS_ERKi30min_V3_S013_14.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	6	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_KMJ_CCS_ERKi30min_V3_S013_14.raw	cell	enrichment of phosphorylated Protein	none	control
Sample 8	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	ERK inhibitor SCH772984	TIO2	enrichment of phosphorylated Protein	run 59	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_KMJ_CCS_ERKi30min_V3_S015.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	7	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_KMJ_CCS_ERKi30min_V3_S015.raw	cell	enrichment of phosphorylated Protein	none	ERK inhibitor SCH772984
Sample 8	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	ERK inhibitor SCH772984	TIO2	enrichment of phosphorylated Protein	run 59	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_KMJ_CCS_ERKi30min_V3_S015.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	7	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_KMJ_CCS_ERKi30min_V3_S015.raw	cell	enrichment of phosphorylated Protein	control	ERK inhibitor SCH772984
Sample 8	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	enrichment of phosphorylated Protein	run 59	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_KMJ_CCS_ERKi30min_V3_S015.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	7	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_KMJ_CCS_ERKi30min_V3_S015.raw	cell	enrichment of phosphorylated Protein	none	control
Sample 8	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	ERK inhibitor SCH772984	TIO2	enrichment of phosphorylated Protein	run 60	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_KMJ_CCS_ERKi30min_V3_S02_12.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	2	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_KMJ_CCS_ERKi30min_V3_S02_12.raw	cell	enrichment of phosphorylated Protein	none	ERK inhibitor SCH772984
Sample 8	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	ERK inhibitor SCH772984	TIO2	enrichment of phosphorylated Protein	run 60	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_KMJ_CCS_ERKi30min_V3_S02_12.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	2	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_KMJ_CCS_ERKi30min_V3_S02_12.raw	cell	enrichment of phosphorylated Protein	control	ERK inhibitor SCH772984
Sample 8	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	enrichment of phosphorylated Protein	run 60	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_KMJ_CCS_ERKi30min_V3_S02_12.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	2	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_KMJ_CCS_ERKi30min_V3_S02_12.raw	cell	enrichment of phosphorylated Protein	none	control
Sample 8	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	ERK inhibitor SCH772984	TIO2	enrichment of phosphorylated Protein	run 61	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_KMJ_CCS_ERKi30min_V3_S03_4_5_6.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	3	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_KMJ_CCS_ERKi30min_V3_S03_4_5_6.raw	cell	enrichment of phosphorylated Protein	none	ERK inhibitor SCH772984
Sample 8	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	ERK inhibitor SCH772984	TIO2	enrichment of phosphorylated Protein	run 61	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_KMJ_CCS_ERKi30min_V3_S03_4_5_6.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	3	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_KMJ_CCS_ERKi30min_V3_S03_4_5_6.raw	cell	enrichment of phosphorylated Protein	control	ERK inhibitor SCH772984
Sample 8	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	enrichment of phosphorylated Protein	run 61	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_KMJ_CCS_ERKi30min_V3_S03_4_5_6.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	3	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_KMJ_CCS_ERKi30min_V3_S03_4_5_6.raw	cell	enrichment of phosphorylated Protein	none	control
Sample 8	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	ERK inhibitor SCH772984	TIO2	enrichment of phosphorylated Protein	run 62	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_KMJ_CCS_ERKi30min_V3_S07_8.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	4	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_KMJ_CCS_ERKi30min_V3_S07_8.raw	cell	enrichment of phosphorylated Protein	none	ERK inhibitor SCH772984
Sample 8	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	ERK inhibitor SCH772984	TIO2	enrichment of phosphorylated Protein	run 62	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_KMJ_CCS_ERKi30min_V3_S07_8.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	4	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_KMJ_CCS_ERKi30min_V3_S07_8.raw	cell	enrichment of phosphorylated Protein	control	ERK inhibitor SCH772984
Sample 8	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	enrichment of phosphorylated Protein	run 62	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_KMJ_CCS_ERKi30min_V3_S07_8.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	4	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_KMJ_CCS_ERKi30min_V3_S07_8.raw	cell	enrichment of phosphorylated Protein	none	control
Sample 8	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	ERK inhibitor SCH772984	TIO2	enrichment of phosphorylated Protein	run 63	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_KMJ_CCS_ERKi30min_V3_S09_10_11.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	5	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_KMJ_CCS_ERKi30min_V3_S09_10_11.raw	cell	enrichment of phosphorylated Protein	none	ERK inhibitor SCH772984
Sample 8	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	ERK inhibitor SCH772984	TIO2	enrichment of phosphorylated Protein	run 63	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_KMJ_CCS_ERKi30min_V3_S09_10_11.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	5	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_KMJ_CCS_ERKi30min_V3_S09_10_11.raw	cell	enrichment of phosphorylated Protein	control	ERK inhibitor SCH772984
Sample 8	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	enrichment of phosphorylated Protein	run 63	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_KMJ_CCS_ERKi30min_V3_S09_10_11.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	5	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_KMJ_CCS_ERKi30min_V3_S09_10_11.raw	cell	enrichment of phosphorylated Protein	none	control
Sample 9	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	ERK inhibitor SCH772984	TIO2	no enrichment	run 64	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/2013114_CCS_ERKi_30min_P01.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	1	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	2013114_CCS_ERKi_30min_P01.raw	cell	no enrichment	none	ERK inhibitor SCH772984
Sample 9	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	ERK inhibitor SCH772984	TIO2	no enrichment	run 64	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/2013114_CCS_ERKi_30min_P01.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	1	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	2013114_CCS_ERKi_30min_P01.raw	cell	no enrichment	control	ERK inhibitor SCH772984
Sample 9	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	no enrichment	run 64	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/2013114_CCS_ERKi_30min_P01.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	1	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	2013114_CCS_ERKi_30min_P01.raw	cell	no enrichment	none	control
Sample 9	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	ERK inhibitor SCH772984	TIO2	no enrichment	run 65	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/2013114_CCS_ERKi_30min_P02.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	2	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	2013114_CCS_ERKi_30min_P02.raw	cell	no enrichment	none	ERK inhibitor SCH772984
Sample 9	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	ERK inhibitor SCH772984	TIO2	no enrichment	run 65	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/2013114_CCS_ERKi_30min_P02.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	2	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	2013114_CCS_ERKi_30min_P02.raw	cell	no enrichment	control	ERK inhibitor SCH772984
Sample 9	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	no enrichment	run 65	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/2013114_CCS_ERKi_30min_P02.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	2	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	2013114_CCS_ERKi_30min_P02.raw	cell	no enrichment	none	control
Sample 9	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	ERK inhibitor SCH772984	TIO2	no enrichment	run 66	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/2013114_CCS_ERKi_30min_P03.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	3	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	2013114_CCS_ERKi_30min_P03.raw	cell	no enrichment	none	ERK inhibitor SCH772984
Sample 9	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	ERK inhibitor SCH772984	TIO2	no enrichment	run 66	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/2013114_CCS_ERKi_30min_P03.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	3	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	2013114_CCS_ERKi_30min_P03.raw	cell	no enrichment	control	ERK inhibitor SCH772984
Sample 9	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	no enrichment	run 66	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/2013114_CCS_ERKi_30min_P03.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	3	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	2013114_CCS_ERKi_30min_P03.raw	cell	no enrichment	none	control
Sample 9	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	ERK inhibitor SCH772984	TIO2	no enrichment	run 67	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/2013114_CCS_ERKi_30min_P04.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	4	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	2013114_CCS_ERKi_30min_P04.raw	cell	no enrichment	none	ERK inhibitor SCH772984
Sample 9	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	ERK inhibitor SCH772984	TIO2	no enrichment	run 67	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/2013114_CCS_ERKi_30min_P04.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	4	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	2013114_CCS_ERKi_30min_P04.raw	cell	no enrichment	control	ERK inhibitor SCH772984
Sample 9	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	no enrichment	run 67	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/2013114_CCS_ERKi_30min_P04.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	4	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	2013114_CCS_ERKi_30min_P04.raw	cell	no enrichment	none	control
Sample 9	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	ERK inhibitor SCH772984	TIO2	no enrichment	run 68	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/2013114_CCS_ERKi_30min_P05.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	5	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	2013114_CCS_ERKi_30min_P05.raw	cell	no enrichment	none	ERK inhibitor SCH772984
Sample 9	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	ERK inhibitor SCH772984	TIO2	no enrichment	run 68	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/2013114_CCS_ERKi_30min_P05.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	5	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	2013114_CCS_ERKi_30min_P05.raw	cell	no enrichment	control	ERK inhibitor SCH772984
Sample 9	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	no enrichment	run 68	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/2013114_CCS_ERKi_30min_P05.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	5	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	2013114_CCS_ERKi_30min_P05.raw	cell	no enrichment	none	control
Sample 9	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	ERK inhibitor SCH772984	TIO2	no enrichment	run 69	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/2013114_CCS_ERKi_30min_P06.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	6	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	2013114_CCS_ERKi_30min_P06.raw	cell	no enrichment	none	ERK inhibitor SCH772984
Sample 9	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	ERK inhibitor SCH772984	TIO2	no enrichment	run 69	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/2013114_CCS_ERKi_30min_P06.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	6	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	2013114_CCS_ERKi_30min_P06.raw	cell	no enrichment	control	ERK inhibitor SCH772984
Sample 9	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	no enrichment	run 69	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/2013114_CCS_ERKi_30min_P06.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	6	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	2013114_CCS_ERKi_30min_P06.raw	cell	no enrichment	none	control
Sample 10	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	MEK inhibitor trametinib	TIO2	no enrichment	run 70	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/2013114_CCS_MEKi_30min_P01.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	1	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	2013114_CCS_MEKi_30min_P01.raw	cell	no enrichment	none	MEK inhibitor trametinib
Sample 10	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	MEK inhibitor trametinib	TIO2	no enrichment	run 70	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/2013114_CCS_MEKi_30min_P01.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	1	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	2013114_CCS_MEKi_30min_P01.raw	cell	no enrichment	control	MEK inhibitor trametinib
Sample 10	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	no enrichment	run 70	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/2013114_CCS_MEKi_30min_P01.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	1	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	2013114_CCS_MEKi_30min_P01.raw	cell	no enrichment	none	control
Sample 10	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	MEK inhibitor trametinib	TIO2	no enrichment	run 71	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/2013114_CCS_MEKi_30min_P02.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	2	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	2013114_CCS_MEKi_30min_P02.raw	cell	no enrichment	none	MEK inhibitor trametinib
Sample 10	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	MEK inhibitor trametinib	TIO2	no enrichment	run 71	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/2013114_CCS_MEKi_30min_P02.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	2	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	2013114_CCS_MEKi_30min_P02.raw	cell	no enrichment	control	MEK inhibitor trametinib
Sample 10	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	no enrichment	run 71	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/2013114_CCS_MEKi_30min_P02.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	2	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	2013114_CCS_MEKi_30min_P02.raw	cell	no enrichment	none	control
Sample 10	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	MEK inhibitor trametinib	TIO2	no enrichment	run 72	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/2013114_CCS_MEKi_30min_P03.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	3	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	2013114_CCS_MEKi_30min_P03.raw	cell	no enrichment	none	MEK inhibitor trametinib
Sample 10	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	MEK inhibitor trametinib	TIO2	no enrichment	run 72	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/2013114_CCS_MEKi_30min_P03.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	3	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	2013114_CCS_MEKi_30min_P03.raw	cell	no enrichment	control	MEK inhibitor trametinib
Sample 10	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	no enrichment	run 72	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/2013114_CCS_MEKi_30min_P03.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	3	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	2013114_CCS_MEKi_30min_P03.raw	cell	no enrichment	none	control
Sample 10	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	MEK inhibitor trametinib	TIO2	no enrichment	run 73	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/2013114_CCS_MEKi_30min_P04.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	4	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	2013114_CCS_MEKi_30min_P04.raw	cell	no enrichment	none	MEK inhibitor trametinib
Sample 10	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	MEK inhibitor trametinib	TIO2	no enrichment	run 73	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/2013114_CCS_MEKi_30min_P04.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	4	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	2013114_CCS_MEKi_30min_P04.raw	cell	no enrichment	control	MEK inhibitor trametinib
Sample 10	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	no enrichment	run 73	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/2013114_CCS_MEKi_30min_P04.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	4	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	2013114_CCS_MEKi_30min_P04.raw	cell	no enrichment	none	control
Sample 10	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	MEK inhibitor trametinib	TIO2	no enrichment	run 74	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/2013114_CCS_MEKi_30min_P05.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	5	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	2013114_CCS_MEKi_30min_P05.raw	cell	no enrichment	none	MEK inhibitor trametinib
Sample 10	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	MEK inhibitor trametinib	TIO2	no enrichment	run 74	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/2013114_CCS_MEKi_30min_P05.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	5	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	2013114_CCS_MEKi_30min_P05.raw	cell	no enrichment	control	MEK inhibitor trametinib
Sample 10	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	no enrichment	run 74	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/2013114_CCS_MEKi_30min_P05.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	5	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	2013114_CCS_MEKi_30min_P05.raw	cell	no enrichment	none	control
Sample 10	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	MEK inhibitor trametinib	TIO2	no enrichment	run 75	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/2013114_CCS_MEKi_30min_P06.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	6	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	2013114_CCS_MEKi_30min_P06.raw	cell	no enrichment	none	MEK inhibitor trametinib
Sample 10	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	MEK inhibitor trametinib	TIO2	no enrichment	run 75	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/2013114_CCS_MEKi_30min_P06.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	6	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	2013114_CCS_MEKi_30min_P06.raw	cell	no enrichment	control	MEK inhibitor trametinib
Sample 10	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	no enrichment	run 75	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/2013114_CCS_MEKi_30min_P06.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	6	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	2013114_CCS_MEKi_30min_P06.raw	cell	no enrichment	none	control
Sample 11	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	BRAF inhibitor dabrafenib	TIO2	no enrichment	run 76	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/2013114_CCS_RAFi_30min_P01.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	1	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	2013114_CCS_RAFi_30min_P01.raw	cell	no enrichment	none	BRAF inhibitor dabrafenib
Sample 11	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	BRAF inhibitor dabrafenib	TIO2	no enrichment	run 76	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/2013114_CCS_RAFi_30min_P01.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	1	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	2013114_CCS_RAFi_30min_P01.raw	cell	no enrichment	control	BRAF inhibitor dabrafenib
Sample 11	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	no enrichment	run 76	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/2013114_CCS_RAFi_30min_P01.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	1	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	2013114_CCS_RAFi_30min_P01.raw	cell	no enrichment	none	control
Sample 11	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	BRAF inhibitor dabrafenib	TIO2	no enrichment	run 77	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/2013114_CCS_RAFi_30min_P02.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	2	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	2013114_CCS_RAFi_30min_P02.raw	cell	no enrichment	none	BRAF inhibitor dabrafenib
Sample 11	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	BRAF inhibitor dabrafenib	TIO2	no enrichment	run 77	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/2013114_CCS_RAFi_30min_P02.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	2	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	2013114_CCS_RAFi_30min_P02.raw	cell	no enrichment	control	BRAF inhibitor dabrafenib
Sample 11	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	no enrichment	run 77	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/2013114_CCS_RAFi_30min_P02.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	2	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	2013114_CCS_RAFi_30min_P02.raw	cell	no enrichment	none	control
Sample 11	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	BRAF inhibitor dabrafenib	TIO2	no enrichment	run 78	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/2013114_CCS_RAFi_30min_P03.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	3	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	2013114_CCS_RAFi_30min_P03.raw	cell	no enrichment	none	BRAF inhibitor dabrafenib
Sample 11	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	BRAF inhibitor dabrafenib	TIO2	no enrichment	run 78	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/2013114_CCS_RAFi_30min_P03.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	3	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	2013114_CCS_RAFi_30min_P03.raw	cell	no enrichment	control	BRAF inhibitor dabrafenib
Sample 11	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	no enrichment	run 78	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/2013114_CCS_RAFi_30min_P03.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	3	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	2013114_CCS_RAFi_30min_P03.raw	cell	no enrichment	none	control
Sample 11	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	BRAF inhibitor dabrafenib	TIO2	no enrichment	run 79	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/2013114_CCS_RAFi_30min_P04.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	4	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	2013114_CCS_RAFi_30min_P04.raw	cell	no enrichment	none	BRAF inhibitor dabrafenib
Sample 11	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	BRAF inhibitor dabrafenib	TIO2	no enrichment	run 79	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/2013114_CCS_RAFi_30min_P04.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	4	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	2013114_CCS_RAFi_30min_P04.raw	cell	no enrichment	control	BRAF inhibitor dabrafenib
Sample 11	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	no enrichment	run 79	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/2013114_CCS_RAFi_30min_P04.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	4	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	2013114_CCS_RAFi_30min_P04.raw	cell	no enrichment	none	control
Sample 11	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	BRAF inhibitor dabrafenib	TIO2	no enrichment	run 80	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/2013114_CCS_RAFi_30min_P05.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	5	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	2013114_CCS_RAFi_30min_P05.raw	cell	no enrichment	none	BRAF inhibitor dabrafenib
Sample 11	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	BRAF inhibitor dabrafenib	TIO2	no enrichment	run 80	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/2013114_CCS_RAFi_30min_P05.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	5	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	2013114_CCS_RAFi_30min_P05.raw	cell	no enrichment	control	BRAF inhibitor dabrafenib
Sample 11	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	no enrichment	run 80	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/2013114_CCS_RAFi_30min_P05.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	5	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	2013114_CCS_RAFi_30min_P05.raw	cell	no enrichment	none	control
Sample 11	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	BRAF inhibitor dabrafenib	TIO2	no enrichment	run 81	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/2013114_CCS_RAFi_30min_P06.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	6	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	2013114_CCS_RAFi_30min_P06.raw	cell	no enrichment	none	BRAF inhibitor dabrafenib
Sample 11	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	BRAF inhibitor dabrafenib	TIO2	no enrichment	run 81	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/2013114_CCS_RAFi_30min_P06.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	6	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	2013114_CCS_RAFi_30min_P06.raw	cell	no enrichment	control	BRAF inhibitor dabrafenib
Sample 11	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	no enrichment	run 81	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/2013114_CCS_RAFi_30min_P06.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	6	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	2013114_CCS_RAFi_30min_P06.raw	cell	no enrichment	none	control
Sample 12	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	BRAF inhibitor dabrafenib	TIO2	no enrichment	run 82	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140211_KMJ_CCS_RAFi_V3_30min_P01.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	1	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140211_KMJ_CCS_RAFi_V3_30min_P01.raw	cell	no enrichment	none	BRAF inhibitor dabrafenib
Sample 12	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	BRAF inhibitor dabrafenib	TIO2	no enrichment	run 82	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140211_KMJ_CCS_RAFi_V3_30min_P01.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	1	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140211_KMJ_CCS_RAFi_V3_30min_P01.raw	cell	no enrichment	control	BRAF inhibitor dabrafenib
Sample 12	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	no enrichment	run 82	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140211_KMJ_CCS_RAFi_V3_30min_P01.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	1	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140211_KMJ_CCS_RAFi_V3_30min_P01.raw	cell	no enrichment	none	control
Sample 12	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	BRAF inhibitor dabrafenib	TIO2	no enrichment	run 83	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140211_KMJ_CCS_RAFi_V3_30min_P02.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	2	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140211_KMJ_CCS_RAFi_V3_30min_P02.raw	cell	no enrichment	none	BRAF inhibitor dabrafenib
Sample 12	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	BRAF inhibitor dabrafenib	TIO2	no enrichment	run 83	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140211_KMJ_CCS_RAFi_V3_30min_P02.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	2	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140211_KMJ_CCS_RAFi_V3_30min_P02.raw	cell	no enrichment	control	BRAF inhibitor dabrafenib
Sample 12	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	no enrichment	run 83	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140211_KMJ_CCS_RAFi_V3_30min_P02.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	2	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140211_KMJ_CCS_RAFi_V3_30min_P02.raw	cell	no enrichment	none	control
Sample 12	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	BRAF inhibitor dabrafenib	TIO2	no enrichment	run 84	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140211_KMJ_CCS_RAFi_V3_30min_P03.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	3	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140211_KMJ_CCS_RAFi_V3_30min_P03.raw	cell	no enrichment	none	BRAF inhibitor dabrafenib
Sample 12	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	BRAF inhibitor dabrafenib	TIO2	no enrichment	run 84	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140211_KMJ_CCS_RAFi_V3_30min_P03.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	3	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140211_KMJ_CCS_RAFi_V3_30min_P03.raw	cell	no enrichment	control	BRAF inhibitor dabrafenib
Sample 12	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	no enrichment	run 84	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140211_KMJ_CCS_RAFi_V3_30min_P03.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	3	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140211_KMJ_CCS_RAFi_V3_30min_P03.raw	cell	no enrichment	none	control
Sample 12	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	BRAF inhibitor dabrafenib	TIO2	no enrichment	run 85	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140211_KMJ_CCS_RAFi_V3_30min_P04.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	4	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140211_KMJ_CCS_RAFi_V3_30min_P04.raw	cell	no enrichment	none	BRAF inhibitor dabrafenib
Sample 12	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	BRAF inhibitor dabrafenib	TIO2	no enrichment	run 85	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140211_KMJ_CCS_RAFi_V3_30min_P04.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	4	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140211_KMJ_CCS_RAFi_V3_30min_P04.raw	cell	no enrichment	control	BRAF inhibitor dabrafenib
Sample 12	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	no enrichment	run 85	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140211_KMJ_CCS_RAFi_V3_30min_P04.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	4	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140211_KMJ_CCS_RAFi_V3_30min_P04.raw	cell	no enrichment	none	control
Sample 12	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	BRAF inhibitor dabrafenib	TIO2	no enrichment	run 86	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140211_KMJ_CCS_RAFi_V3_30min_P05.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	5	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140211_KMJ_CCS_RAFi_V3_30min_P05.raw	cell	no enrichment	none	BRAF inhibitor dabrafenib
Sample 12	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	BRAF inhibitor dabrafenib	TIO2	no enrichment	run 86	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140211_KMJ_CCS_RAFi_V3_30min_P05.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	5	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140211_KMJ_CCS_RAFi_V3_30min_P05.raw	cell	no enrichment	control	BRAF inhibitor dabrafenib
Sample 12	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	no enrichment	run 86	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140211_KMJ_CCS_RAFi_V3_30min_P05.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	5	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140211_KMJ_CCS_RAFi_V3_30min_P05.raw	cell	no enrichment	none	control
Sample 12	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	BRAF inhibitor dabrafenib	TIO2	no enrichment	run 87	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140211_KMJ_CCS_RAFi_V3_30min_P06.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	6	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140211_KMJ_CCS_RAFi_V3_30min_P06.raw	cell	no enrichment	none	BRAF inhibitor dabrafenib
Sample 12	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	BRAF inhibitor dabrafenib	TIO2	no enrichment	run 87	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140211_KMJ_CCS_RAFi_V3_30min_P06.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	6	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140211_KMJ_CCS_RAFi_V3_30min_P06.raw	cell	no enrichment	control	BRAF inhibitor dabrafenib
Sample 12	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	no enrichment	run 87	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140211_KMJ_CCS_RAFi_V3_30min_P06.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	6	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140211_KMJ_CCS_RAFi_V3_30min_P06.raw	cell	no enrichment	none	control
Sample 13	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	MEK inhibitor trametinib	TIO2	no enrichment	run 88	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140213_KMJ_CCS_MEKi_V3_30min_P01.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	1	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140213_KMJ_CCS_MEKi_V3_30min_P01.raw	cell	no enrichment	none	MEK inhibitor trametinib
Sample 13	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	MEK inhibitor trametinib	TIO2	no enrichment	run 88	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140213_KMJ_CCS_MEKi_V3_30min_P01.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	1	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140213_KMJ_CCS_MEKi_V3_30min_P01.raw	cell	no enrichment	control	MEK inhibitor trametinib
Sample 13	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	no enrichment	run 88	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140213_KMJ_CCS_MEKi_V3_30min_P01.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	1	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140213_KMJ_CCS_MEKi_V3_30min_P01.raw	cell	no enrichment	none	control
Sample 13	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	MEK inhibitor trametinib	TIO2	no enrichment	run 89	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140213_KMJ_CCS_MEKi_V3_30min_P02.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	2	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140213_KMJ_CCS_MEKi_V3_30min_P02.raw	cell	no enrichment	none	MEK inhibitor trametinib
Sample 13	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	MEK inhibitor trametinib	TIO2	no enrichment	run 89	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140213_KMJ_CCS_MEKi_V3_30min_P02.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	2	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140213_KMJ_CCS_MEKi_V3_30min_P02.raw	cell	no enrichment	control	MEK inhibitor trametinib
Sample 13	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	no enrichment	run 89	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140213_KMJ_CCS_MEKi_V3_30min_P02.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	2	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140213_KMJ_CCS_MEKi_V3_30min_P02.raw	cell	no enrichment	none	control
Sample 13	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	MEK inhibitor trametinib	TIO2	no enrichment	run 90	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140213_KMJ_CCS_MEKi_V3_30min_P03.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	3	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140213_KMJ_CCS_MEKi_V3_30min_P03.raw	cell	no enrichment	none	MEK inhibitor trametinib
Sample 13	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	MEK inhibitor trametinib	TIO2	no enrichment	run 90	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140213_KMJ_CCS_MEKi_V3_30min_P03.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	3	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140213_KMJ_CCS_MEKi_V3_30min_P03.raw	cell	no enrichment	control	MEK inhibitor trametinib
Sample 13	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	no enrichment	run 90	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140213_KMJ_CCS_MEKi_V3_30min_P03.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	3	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140213_KMJ_CCS_MEKi_V3_30min_P03.raw	cell	no enrichment	none	control
Sample 13	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	MEK inhibitor trametinib	TIO2	no enrichment	run 91	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140213_KMJ_CCS_MEKi_V3_30min_P04.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	4	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140213_KMJ_CCS_MEKi_V3_30min_P04.raw	cell	no enrichment	none	MEK inhibitor trametinib
Sample 13	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	MEK inhibitor trametinib	TIO2	no enrichment	run 91	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140213_KMJ_CCS_MEKi_V3_30min_P04.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	4	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140213_KMJ_CCS_MEKi_V3_30min_P04.raw	cell	no enrichment	control	MEK inhibitor trametinib
Sample 13	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	no enrichment	run 91	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140213_KMJ_CCS_MEKi_V3_30min_P04.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	4	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140213_KMJ_CCS_MEKi_V3_30min_P04.raw	cell	no enrichment	none	control
Sample 13	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	MEK inhibitor trametinib	TIO2	no enrichment	run 92	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140213_KMJ_CCS_MEKi_V3_30min_P05.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	5	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140213_KMJ_CCS_MEKi_V3_30min_P05.raw	cell	no enrichment	none	MEK inhibitor trametinib
Sample 13	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	MEK inhibitor trametinib	TIO2	no enrichment	run 92	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140213_KMJ_CCS_MEKi_V3_30min_P05.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	5	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140213_KMJ_CCS_MEKi_V3_30min_P05.raw	cell	no enrichment	control	MEK inhibitor trametinib
Sample 13	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	no enrichment	run 92	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140213_KMJ_CCS_MEKi_V3_30min_P05.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	5	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140213_KMJ_CCS_MEKi_V3_30min_P05.raw	cell	no enrichment	none	control
Sample 13	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	MEK inhibitor trametinib	TIO2	no enrichment	run 93	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140213_KMJ_CCS_MEKi_V3_30min_P06.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	6	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140213_KMJ_CCS_MEKi_V3_30min_P06.raw	cell	no enrichment	none	MEK inhibitor trametinib
Sample 13	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	MEK inhibitor trametinib	TIO2	no enrichment	run 93	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140213_KMJ_CCS_MEKi_V3_30min_P06.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	6	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140213_KMJ_CCS_MEKi_V3_30min_P06.raw	cell	no enrichment	control	MEK inhibitor trametinib
Sample 13	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	no enrichment	run 93	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140213_KMJ_CCS_MEKi_V3_30min_P06.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	6	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140213_KMJ_CCS_MEKi_V3_30min_P06.raw	cell	no enrichment	none	control
Sample 14	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	MEK inhibitor trametinib	TIO2	no enrichment	run 94	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_CCS_EV_A375_MEKi_30min_v4_P01.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	1	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_CCS_EV_A375_MEKi_30min_v4_P01.raw	cell	no enrichment	none	MEK inhibitor trametinib
Sample 14	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	MEK inhibitor trametinib	TIO2	no enrichment	run 94	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_CCS_EV_A375_MEKi_30min_v4_P01.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	1	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_CCS_EV_A375_MEKi_30min_v4_P01.raw	cell	no enrichment	control	MEK inhibitor trametinib
Sample 14	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	no enrichment	run 94	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_CCS_EV_A375_MEKi_30min_v4_P01.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	1	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_CCS_EV_A375_MEKi_30min_v4_P01.raw	cell	no enrichment	none	control
Sample 14	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	MEK inhibitor trametinib	TIO2	no enrichment	run 95	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_CCS_EV_A375_MEKi_30min_v4_P02.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	2	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_CCS_EV_A375_MEKi_30min_v4_P02.raw	cell	no enrichment	none	MEK inhibitor trametinib
Sample 14	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	MEK inhibitor trametinib	TIO2	no enrichment	run 95	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_CCS_EV_A375_MEKi_30min_v4_P02.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	2	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_CCS_EV_A375_MEKi_30min_v4_P02.raw	cell	no enrichment	control	MEK inhibitor trametinib
Sample 14	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	no enrichment	run 95	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_CCS_EV_A375_MEKi_30min_v4_P02.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	2	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_CCS_EV_A375_MEKi_30min_v4_P02.raw	cell	no enrichment	none	control
Sample 14	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	MEK inhibitor trametinib	TIO2	no enrichment	run 96	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_CCS_EV_A375_MEKi_30min_v4_P03.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	3	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_CCS_EV_A375_MEKi_30min_v4_P03.raw	cell	no enrichment	none	MEK inhibitor trametinib
Sample 14	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	MEK inhibitor trametinib	TIO2	no enrichment	run 96	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_CCS_EV_A375_MEKi_30min_v4_P03.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	3	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_CCS_EV_A375_MEKi_30min_v4_P03.raw	cell	no enrichment	control	MEK inhibitor trametinib
Sample 14	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	no enrichment	run 96	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_CCS_EV_A375_MEKi_30min_v4_P03.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	3	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_CCS_EV_A375_MEKi_30min_v4_P03.raw	cell	no enrichment	none	control
Sample 14	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	MEK inhibitor trametinib	TIO2	no enrichment	run 97	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_CCS_EV_A375_MEKi_30min_v4_P04.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	4	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_CCS_EV_A375_MEKi_30min_v4_P04.raw	cell	no enrichment	none	MEK inhibitor trametinib
Sample 14	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	MEK inhibitor trametinib	TIO2	no enrichment	run 97	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_CCS_EV_A375_MEKi_30min_v4_P04.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	4	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_CCS_EV_A375_MEKi_30min_v4_P04.raw	cell	no enrichment	control	MEK inhibitor trametinib
Sample 14	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	no enrichment	run 97	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_CCS_EV_A375_MEKi_30min_v4_P04.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	4	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_CCS_EV_A375_MEKi_30min_v4_P04.raw	cell	no enrichment	none	control
Sample 14	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	MEK inhibitor trametinib	TIO2	no enrichment	run 98	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_CCS_EV_A375_MEKi_30min_v4_P05.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	5	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_CCS_EV_A375_MEKi_30min_v4_P05.raw	cell	no enrichment	none	MEK inhibitor trametinib
Sample 14	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	MEK inhibitor trametinib	TIO2	no enrichment	run 98	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_CCS_EV_A375_MEKi_30min_v4_P05.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	5	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_CCS_EV_A375_MEKi_30min_v4_P05.raw	cell	no enrichment	control	MEK inhibitor trametinib
Sample 14	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	no enrichment	run 98	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_CCS_EV_A375_MEKi_30min_v4_P05.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	5	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_CCS_EV_A375_MEKi_30min_v4_P05.raw	cell	no enrichment	none	control
Sample 14	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	MEK inhibitor trametinib	TIO2	no enrichment	run 99	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_CCS_EV_A375_MEKi_30min_v4_P06.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	6	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_CCS_EV_A375_MEKi_30min_v4_P06.raw	cell	no enrichment	none	MEK inhibitor trametinib
Sample 14	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	MEK inhibitor trametinib	TIO2	no enrichment	run 99	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_CCS_EV_A375_MEKi_30min_v4_P06.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	6	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_CCS_EV_A375_MEKi_30min_v4_P06.raw	cell	no enrichment	control	MEK inhibitor trametinib
Sample 14	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	no enrichment	run 99	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_CCS_EV_A375_MEKi_30min_v4_P06.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	6	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_CCS_EV_A375_MEKi_30min_v4_P06.raw	cell	no enrichment	none	control
Sample 15	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	ERK inhibitor SCH772984	TIO2	no enrichment	run 100	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_KMJ_CCS_ERKi_V3_30min_P01.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	1	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_KMJ_CCS_ERKi_V3_30min_P01.raw	cell	no enrichment	none	ERK inhibitor SCH772984
Sample 15	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	ERK inhibitor SCH772984	TIO2	no enrichment	run 100	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_KMJ_CCS_ERKi_V3_30min_P01.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	1	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_KMJ_CCS_ERKi_V3_30min_P01.raw	cell	no enrichment	control	ERK inhibitor SCH772984
Sample 15	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	no enrichment	run 100	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_KMJ_CCS_ERKi_V3_30min_P01.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	1	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_KMJ_CCS_ERKi_V3_30min_P01.raw	cell	no enrichment	none	control
Sample 15	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	ERK inhibitor SCH772984	TIO2	no enrichment	run 101	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_KMJ_CCS_ERKi_V3_30min_P02.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	2	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_KMJ_CCS_ERKi_V3_30min_P02.raw	cell	no enrichment	none	ERK inhibitor SCH772984
Sample 15	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	ERK inhibitor SCH772984	TIO2	no enrichment	run 101	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_KMJ_CCS_ERKi_V3_30min_P02.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	2	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_KMJ_CCS_ERKi_V3_30min_P02.raw	cell	no enrichment	none	ERK inhibitor SCH772984
Sample 15	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	ERK inhibitor SCH772984	TIO2	no enrichment	run 101	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_KMJ_CCS_ERKi_V3_30min_P02.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	2	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_KMJ_CCS_ERKi_V3_30min_P02.raw	cell	no enrichment	none	ERK inhibitor SCH772984
Sample 15	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	ERK inhibitor SCH772984	TIO2	no enrichment	run 102	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_KMJ_CCS_ERKi_V3_30min_P03.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	3	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_KMJ_CCS_ERKi_V3_30min_P03.raw	cell	no enrichment	none	ERK inhibitor SCH772984
Sample 15	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	ERK inhibitor SCH772984	TIO2	no enrichment	run 102	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_KMJ_CCS_ERKi_V3_30min_P03.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	3	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_KMJ_CCS_ERKi_V3_30min_P03.raw	cell	no enrichment	none	ERK inhibitor SCH772984
Sample 15	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	ERK inhibitor SCH772984	TIO2	no enrichment	run 102	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_KMJ_CCS_ERKi_V3_30min_P03.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	3	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_KMJ_CCS_ERKi_V3_30min_P03.raw	cell	no enrichment	none	ERK inhibitor SCH772984
Sample 15	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	ERK inhibitor SCH772984	TIO2	no enrichment	run 103	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_KMJ_CCS_ERKi_V3_30min_P04.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	4	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_KMJ_CCS_ERKi_V3_30min_P04.raw	cell	no enrichment	none	ERK inhibitor SCH772984
Sample 15	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	ERK inhibitor SCH772984	TIO2	no enrichment	run 103	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_KMJ_CCS_ERKi_V3_30min_P04.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	4	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_KMJ_CCS_ERKi_V3_30min_P04.raw	cell	no enrichment	none	ERK inhibitor SCH772984
Sample 15	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	ERK inhibitor SCH772984	TIO2	no enrichment	run 103	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_KMJ_CCS_ERKi_V3_30min_P04.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	4	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_KMJ_CCS_ERKi_V3_30min_P04.raw	cell	no enrichment	none	ERK inhibitor SCH772984
Sample 15	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	ERK inhibitor SCH772984	TIO2	no enrichment	run 104	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_KMJ_CCS_ERKi_V3_30min_P05.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	5	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_KMJ_CCS_ERKi_V3_30min_P05.raw	cell	no enrichment	none	ERK inhibitor SCH772984
Sample 15	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	ERK inhibitor SCH772984	TIO2	no enrichment	run 104	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_KMJ_CCS_ERKi_V3_30min_P05.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	5	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_KMJ_CCS_ERKi_V3_30min_P05.raw	cell	no enrichment	none	ERK inhibitor SCH772984
Sample 15	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	ERK inhibitor SCH772984	TIO2	no enrichment	run 104	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_KMJ_CCS_ERKi_V3_30min_P05.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	5	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_KMJ_CCS_ERKi_V3_30min_P05.raw	cell	no enrichment	none	ERK inhibitor SCH772984
Sample 15	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	ERK inhibitor SCH772984	TIO2	no enrichment	run 105	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_KMJ_CCS_ERKi_V3_30min_P06.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	6	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_KMJ_CCS_ERKi_V3_30min_P06.raw	cell	no enrichment	none	ERK inhibitor SCH772984
Sample 15	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	ERK inhibitor SCH772984	TIO2	no enrichment	run 105	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_KMJ_CCS_ERKi_V3_30min_P06.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	6	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_KMJ_CCS_ERKi_V3_30min_P06.raw	cell	no enrichment	none	ERK inhibitor SCH772984
Sample 15	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	ERK inhibitor SCH772984	TIO2	no enrichment	run 105	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140214_KMJ_CCS_ERKi_V3_30min_P06.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	6	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140214_KMJ_CCS_ERKi_V3_30min_P06.raw	cell	no enrichment	none	ERK inhibitor SCH772984
Sample 16	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	BRAF inhibitor dabrafenib	TIO2	no enrichment	run 106	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140320_CCS_EV_A375_RAFi_30min_v4_P01.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	1	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140320_CCS_EV_A375_RAFi_30min_v4_P01.raw	cell	no enrichment	none	BRAF inhibitor dabrafenib
Sample 16	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	BRAF inhibitor dabrafenib	TIO2	no enrichment	run 106	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140320_CCS_EV_A375_RAFi_30min_v4_P01.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	1	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140320_CCS_EV_A375_RAFi_30min_v4_P01.raw	cell	no enrichment	control	BRAF inhibitor dabrafenib
Sample 16	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	no enrichment	run 106	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140320_CCS_EV_A375_RAFi_30min_v4_P01.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	1	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140320_CCS_EV_A375_RAFi_30min_v4_P01.raw	cell	no enrichment	none	control
Sample 16	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	BRAF inhibitor dabrafenib	TIO2	no enrichment	run 107	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140320_CCS_EV_A375_RAFi_30min_v4_P02.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	2	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140320_CCS_EV_A375_RAFi_30min_v4_P02.raw	cell	no enrichment	none	BRAF inhibitor dabrafenib
Sample 16	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	BRAF inhibitor dabrafenib	TIO2	no enrichment	run 107	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140320_CCS_EV_A375_RAFi_30min_v4_P02.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	2	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140320_CCS_EV_A375_RAFi_30min_v4_P02.raw	cell	no enrichment	control	BRAF inhibitor dabrafenib
Sample 16	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	no enrichment	run 107	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140320_CCS_EV_A375_RAFi_30min_v4_P02.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	2	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140320_CCS_EV_A375_RAFi_30min_v4_P02.raw	cell	no enrichment	none	control
Sample 16	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	BRAF inhibitor dabrafenib	TIO2	no enrichment	run 108	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140320_CCS_EV_A375_RAFi_30min_v4_P03.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	3	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140320_CCS_EV_A375_RAFi_30min_v4_P03.raw	cell	no enrichment	none	BRAF inhibitor dabrafenib
Sample 16	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	BRAF inhibitor dabrafenib	TIO2	no enrichment	run 108	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140320_CCS_EV_A375_RAFi_30min_v4_P03.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	3	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140320_CCS_EV_A375_RAFi_30min_v4_P03.raw	cell	no enrichment	control	BRAF inhibitor dabrafenib
Sample 16	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	no enrichment	run 108	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140320_CCS_EV_A375_RAFi_30min_v4_P03.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	3	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140320_CCS_EV_A375_RAFi_30min_v4_P03.raw	cell	no enrichment	none	control
Sample 16	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	BRAF inhibitor dabrafenib	TIO2	no enrichment	run 109	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140320_CCS_EV_A375_RAFi_30min_v4_P04.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	4	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140320_CCS_EV_A375_RAFi_30min_v4_P04.raw	cell	no enrichment	none	BRAF inhibitor dabrafenib
Sample 16	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	BRAF inhibitor dabrafenib	TIO2	no enrichment	run 109	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140320_CCS_EV_A375_RAFi_30min_v4_P04.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	4	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140320_CCS_EV_A375_RAFi_30min_v4_P04.raw	cell	no enrichment	control	BRAF inhibitor dabrafenib
Sample 16	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	no enrichment	run 109	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140320_CCS_EV_A375_RAFi_30min_v4_P04.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	4	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140320_CCS_EV_A375_RAFi_30min_v4_P04.raw	cell	no enrichment	none	control
Sample 16	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	BRAF inhibitor dabrafenib	TIO2	no enrichment	run 110	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140320_CCS_EV_A375_RAFi_30min_v4_P05.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	5	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140320_CCS_EV_A375_RAFi_30min_v4_P05.raw	cell	no enrichment	none	BRAF inhibitor dabrafenib
Sample 16	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	BRAF inhibitor dabrafenib	TIO2	no enrichment	run 110	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140320_CCS_EV_A375_RAFi_30min_v4_P05.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	5	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140320_CCS_EV_A375_RAFi_30min_v4_P05.raw	cell	no enrichment	control	BRAF inhibitor dabrafenib
Sample 16	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	no enrichment	run 110	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140320_CCS_EV_A375_RAFi_30min_v4_P05.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	5	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140320_CCS_EV_A375_RAFi_30min_v4_P05.raw	cell	no enrichment	none	control
Sample 16	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	BRAF inhibitor dabrafenib	TIO2	no enrichment	run 111	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140320_CCS_EV_A375_RAFi_30min_v4_P06.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	6	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140320_CCS_EV_A375_RAFi_30min_v4_P06.raw	cell	no enrichment	none	BRAF inhibitor dabrafenib
Sample 16	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	BRAF inhibitor dabrafenib	TIO2	no enrichment	run 111	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140320_CCS_EV_A375_RAFi_30min_v4_P06.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	6	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140320_CCS_EV_A375_RAFi_30min_v4_P06.raw	cell	no enrichment	control	BRAF inhibitor dabrafenib
Sample 16	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	no enrichment	run 111	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140320_CCS_EV_A375_RAFi_30min_v4_P06.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	6	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140320_CCS_EV_A375_RAFi_30min_v4_P06.raw	cell	no enrichment	none	control
Sample 17	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	ERK inhibitor SCH772984	TIO2	no enrichment	run 112	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140515_CCS_JL_ERKi_30min_V5_P1.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	1	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140515_CCS_JL_ERKi_30min_V5_P1.raw	cell	no enrichment	none	ERK inhibitor SCH772984
Sample 17	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	ERK inhibitor SCH772984	TIO2	no enrichment	run 112	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140515_CCS_JL_ERKi_30min_V5_P1.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	1	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140515_CCS_JL_ERKi_30min_V5_P1.raw	cell	no enrichment	control	ERK inhibitor SCH772984
Sample 17	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	no enrichment	run 112	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140515_CCS_JL_ERKi_30min_V5_P1.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	1	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140515_CCS_JL_ERKi_30min_V5_P1.raw	cell	no enrichment	none	control
Sample 17	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	ERK inhibitor SCH772984	TIO2	no enrichment	run 113	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140515_CCS_JL_ERKi_30min_V5_P2.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	2	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140515_CCS_JL_ERKi_30min_V5_P2.raw	cell	no enrichment	none	ERK inhibitor SCH772984
Sample 17	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	ERK inhibitor SCH772984	TIO2	no enrichment	run 113	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140515_CCS_JL_ERKi_30min_V5_P2.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	2	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140515_CCS_JL_ERKi_30min_V5_P2.raw	cell	no enrichment	control	ERK inhibitor SCH772984
Sample 17	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	no enrichment	run 113	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140515_CCS_JL_ERKi_30min_V5_P2.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	2	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140515_CCS_JL_ERKi_30min_V5_P2.raw	cell	no enrichment	none	control
Sample 17	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	ERK inhibitor SCH772984	TIO2	no enrichment	run 114	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140515_CCS_JL_ERKi_30min_V5_P3.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	3	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140515_CCS_JL_ERKi_30min_V5_P3.raw	cell	no enrichment	none	ERK inhibitor SCH772984
Sample 17	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	ERK inhibitor SCH772984	TIO2	no enrichment	run 114	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140515_CCS_JL_ERKi_30min_V5_P3.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	3	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140515_CCS_JL_ERKi_30min_V5_P3.raw	cell	no enrichment	control	ERK inhibitor SCH772984
Sample 17	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	no enrichment	run 114	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140515_CCS_JL_ERKi_30min_V5_P3.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	3	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140515_CCS_JL_ERKi_30min_V5_P3.raw	cell	no enrichment	none	control
Sample 17	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	ERK inhibitor SCH772984	TIO2	no enrichment	run 115	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140515_CCS_JL_ERKi_30min_V5_P4.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	4	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140515_CCS_JL_ERKi_30min_V5_P4.raw	cell	no enrichment	none	ERK inhibitor SCH772984
Sample 17	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	ERK inhibitor SCH772984	TIO2	no enrichment	run 115	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140515_CCS_JL_ERKi_30min_V5_P4.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	4	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140515_CCS_JL_ERKi_30min_V5_P4.raw	cell	no enrichment	control	ERK inhibitor SCH772984
Sample 17	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	no enrichment	run 115	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140515_CCS_JL_ERKi_30min_V5_P4.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	4	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140515_CCS_JL_ERKi_30min_V5_P4.raw	cell	no enrichment	none	control
Sample 17	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	ERK inhibitor SCH772984	TIO2	no enrichment	run 116	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140515_CCS_JL_ERKi_30min_V5_P5.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	5	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140515_CCS_JL_ERKi_30min_V5_P5.raw	cell	no enrichment	none	ERK inhibitor SCH772984
Sample 17	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	ERK inhibitor SCH772984	TIO2	no enrichment	run 116	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140515_CCS_JL_ERKi_30min_V5_P5.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	5	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140515_CCS_JL_ERKi_30min_V5_P5.raw	cell	no enrichment	control	ERK inhibitor SCH772984
Sample 17	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	no enrichment	run 116	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140515_CCS_JL_ERKi_30min_V5_P5.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	5	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140515_CCS_JL_ERKi_30min_V5_P5.raw	cell	no enrichment	none	control
Sample 17	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	ERK inhibitor SCH772984	TIO2	no enrichment	run 117	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140515_CCS_JL_ERKi_30min_V5_P6.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	6	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140515_CCS_JL_ERKi_30min_V5_P6.raw	cell	no enrichment	none	ERK inhibitor SCH772984
Sample 17	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	ERK inhibitor SCH772984	TIO2	no enrichment	run 117	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140515_CCS_JL_ERKi_30min_V5_P6.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	6	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140515_CCS_JL_ERKi_30min_V5_P6.raw	cell	no enrichment	control	ERK inhibitor SCH772984
Sample 17	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	no enrichment	run 117	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140515_CCS_JL_ERKi_30min_V5_P6.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	6	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	not applicable	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140515_CCS_JL_ERKi_30min_V5_P6.raw	cell	no enrichment	none	control
Sample 18	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	ERK inhibitor SCH772984	TIO2	enrichment of phosphorylated Protein	run 118	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140515_CCS_JL_ERKi_30min_V5_S01.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	1	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140515_CCS_JL_ERKi_30min_V5_S01.raw	cell	enrichment of phosphorylated Protein	none	ERK inhibitor SCH772984
Sample 18	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	ERK inhibitor SCH772984	TIO2	enrichment of phosphorylated Protein	run 118	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140515_CCS_JL_ERKi_30min_V5_S01.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	1	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140515_CCS_JL_ERKi_30min_V5_S01.raw	cell	enrichment of phosphorylated Protein	control	ERK inhibitor SCH772984
Sample 18	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	enrichment of phosphorylated Protein	run 118	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140515_CCS_JL_ERKi_30min_V5_S01.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	1	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140515_CCS_JL_ERKi_30min_V5_S01.raw	cell	enrichment of phosphorylated Protein	none	control
Sample 18	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	ERK inhibitor SCH772984	TIO2	enrichment of phosphorylated Protein	run 119	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140515_CCS_JL_ERKi_30min_V5_S013_14.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	6	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140515_CCS_JL_ERKi_30min_V5_S013_14.raw	cell	enrichment of phosphorylated Protein	none	ERK inhibitor SCH772984
Sample 18	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	ERK inhibitor SCH772984	TIO2	enrichment of phosphorylated Protein	run 119	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140515_CCS_JL_ERKi_30min_V5_S013_14.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	6	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140515_CCS_JL_ERKi_30min_V5_S013_14.raw	cell	enrichment of phosphorylated Protein	control	ERK inhibitor SCH772984
Sample 18	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	enrichment of phosphorylated Protein	run 119	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140515_CCS_JL_ERKi_30min_V5_S013_14.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	6	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140515_CCS_JL_ERKi_30min_V5_S013_14.raw	cell	enrichment of phosphorylated Protein	none	control
Sample 18	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	ERK inhibitor SCH772984	TIO2	enrichment of phosphorylated Protein	run 120	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140515_CCS_JL_ERKi_30min_V5_S015.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	7	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140515_CCS_JL_ERKi_30min_V5_S015.raw	cell	enrichment of phosphorylated Protein	none	ERK inhibitor SCH772984
Sample 18	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	ERK inhibitor SCH772984	TIO2	enrichment of phosphorylated Protein	run 120	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140515_CCS_JL_ERKi_30min_V5_S015.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	7	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140515_CCS_JL_ERKi_30min_V5_S015.raw	cell	enrichment of phosphorylated Protein	control	ERK inhibitor SCH772984
Sample 18	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	enrichment of phosphorylated Protein	run 120	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140515_CCS_JL_ERKi_30min_V5_S015.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	7	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140515_CCS_JL_ERKi_30min_V5_S015.raw	cell	enrichment of phosphorylated Protein	none	control
Sample 18	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	ERK inhibitor SCH772984	TIO2	enrichment of phosphorylated Protein	run 121	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140515_CCS_JL_ERKi_30min_V5_S02_12.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	2	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140515_CCS_JL_ERKi_30min_V5_S02_12.raw	cell	enrichment of phosphorylated Protein	none	ERK inhibitor SCH772984
Sample 18	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	ERK inhibitor SCH772984	TIO2	enrichment of phosphorylated Protein	run 121	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140515_CCS_JL_ERKi_30min_V5_S02_12.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	2	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140515_CCS_JL_ERKi_30min_V5_S02_12.raw	cell	enrichment of phosphorylated Protein	control	ERK inhibitor SCH772984
Sample 18	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	enrichment of phosphorylated Protein	run 121	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140515_CCS_JL_ERKi_30min_V5_S02_12.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	2	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140515_CCS_JL_ERKi_30min_V5_S02_12.raw	cell	enrichment of phosphorylated Protein	none	control
Sample 18	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	ERK inhibitor SCH772984	TIO2	enrichment of phosphorylated Protein	run 122	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140515_CCS_JL_ERKi_30min_V5_S03_4_5_6.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	3	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140515_CCS_JL_ERKi_30min_V5_S03_4_5_6.raw	cell	enrichment of phosphorylated Protein	none	ERK inhibitor SCH772984
Sample 18	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	ERK inhibitor SCH772984	TIO2	enrichment of phosphorylated Protein	run 122	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140515_CCS_JL_ERKi_30min_V5_S03_4_5_6.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	3	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140515_CCS_JL_ERKi_30min_V5_S03_4_5_6.raw	cell	enrichment of phosphorylated Protein	control	ERK inhibitor SCH772984
Sample 18	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	enrichment of phosphorylated Protein	run 122	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140515_CCS_JL_ERKi_30min_V5_S03_4_5_6.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	3	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140515_CCS_JL_ERKi_30min_V5_S03_4_5_6.raw	cell	enrichment of phosphorylated Protein	none	control
Sample 18	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	ERK inhibitor SCH772984	TIO2	enrichment of phosphorylated Protein	run 123	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140515_CCS_JL_ERKi_30min_V5_S07_8.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	4	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140515_CCS_JL_ERKi_30min_V5_S07_8.raw	cell	enrichment of phosphorylated Protein	none	ERK inhibitor SCH772984
Sample 18	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	ERK inhibitor SCH772984	TIO2	enrichment of phosphorylated Protein	run 123	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140515_CCS_JL_ERKi_30min_V5_S07_8.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	4	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140515_CCS_JL_ERKi_30min_V5_S07_8.raw	cell	enrichment of phosphorylated Protein	control	ERK inhibitor SCH772984
Sample 18	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	enrichment of phosphorylated Protein	run 123	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140515_CCS_JL_ERKi_30min_V5_S07_8.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	4	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140515_CCS_JL_ERKi_30min_V5_S07_8.raw	cell	enrichment of phosphorylated Protein	none	control
Sample 18	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	ERK inhibitor SCH772984	TIO2	enrichment of phosphorylated Protein	run 124	SILAC heavy	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140515_CCS_JL_ERKi_30min_V5_S09_10_11.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	5	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140515_CCS_JL_ERKi_30min_V5_S09_10_11.raw	cell	enrichment of phosphorylated Protein	none	ERK inhibitor SCH772984
Sample 18	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	control	ERK inhibitor SCH772984	TIO2	enrichment of phosphorylated Protein	run 124	SILAC medium	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140515_CCS_JL_ERKi_30min_V5_S09_10_11.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	5	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140515_CCS_JL_ERKi_30min_V5_S09_10_11.raw	cell	enrichment of phosphorylated Protein	control	ERK inhibitor SCH772984
Sample 18	Homo sapiens	not applicable	54Y	not available	female	not available	malignant melanoma	epithelial	A375	none	control	TIO2	enrichment of phosphorylated Protein	run 124	SILAC light	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/11/PXD013923/20140515_CCS_JL_ERKi_30min_V5_S09_10_11.raw	NT=Strong cation-exchange chromatography (SCX);AC=PRIDE:0000561	5	NT=Q Exactive;AC=MS:1001911	NT=Carbamidomethyl;TA=C;MT=fixed;AC=UNIMOD:4	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Acetyl;AC=UNIMOD:1;PP=Protein N-term;MT=variable	"NT=Phospho;MT=variable;TA=S,T,Y;AC=UNIMOD:21"	NT=Trypsin; AC=MS:1001251	NT=Lys-C;AC=MS:1001309	not available	not available	20140515_CCS_JL_ERKi_30min_V5_S09_10_11.raw	cell	enrichment of phosphorylated Protein	none	control
